Biopôle Clermont-Limagne
Technology park for life sciences


on Biopôle Clermont-Limagne

The EIB, with the support of the European Commission, is financing a €30 million loan for Carbios’ enzymatic recycling technology to support the Circular Economy.

Carbios and the European Investment Bank (EIB) announced today the signing of a €30 million loan agreement supported by the European Commission InnovFin Energy Demonstration Programme.

Read more

The aim of this type of financing is to support high potential innovative projects developed by companies aiming to achieve transformative changes aligned with the EU Climate goals and contribute to the EU industry’s leadership in the development of sustainable technologies.

Carbios fully meets these criteria with its world’s first enzyme-based processes, which have the potential to contribute to the plastic’s industry sustainability.

This loan has been granted to support the strategic industrial and commercial development of Carbios technology of PET enzymatic recycling aiming at transforming post-consumer PET plastic and polyester fibers to their original building blocks (monomers) through a biological enzymatic depolymerization process that can then be used for feedstock as new recycled PET suitable for all original applications.

This disruptive technology that could accelerate the transition to a plastics Circular Economy allowing PET plastic producers to replace petrochemicals with monomers from PET plastic waste, resulting in 100% recycled PET content in new products.

STRAINCHEM enters the semi-industrial phase with France Relance.

Last October, the French Government presented the 58 new winners of the Relocation France Relance call for projects. Led by the Ministère de l’Économie, des Finances et de la Relance, this program supports strategic investments in critical sectors, including health, chemistry and agri-food.

Read more

One of them is StrainChem, a pharmaceutical company run by Dr.Audrey Serre and Dr.Jean-Jacques Youte, and based on the Biopôle Clermont-Limagne since 2017. It specializes in the synthesis of molecules with high therapeutic potential, biopolymers (e.g., peptide, oligosaccharide, and oligonucleotide) and has developed and patented innovative, efficient, cost-effective and ecological processes to produce these molecules.

The Strainchem project, called SLiPONS (Sustainable LIquid Phase OligoNucleotide Synthesis), aims to set up a production unit for oligonucleotides, molecules used for innovative therapies such as gene therapy. France Relance’s support will accelerate its semi-industrial deployment to meet the needs of pharmaceutical companies, biotechs, and universities. It is expected to create some 20 jobs.

Carbios receives support from the European Commission through the LIFE program.

Carbios, a pioneer in the development of enzymatic solutions dedicated to the end-of-life of plastic and textile polymers, has received alongside two significant partners T.EN Zimmer GmbH and Deloitte € 3.3 million - including € 3 million for Carbios – in the form of a European grant. 


Read more

T.EN Zimmer GmbH, will provide its expertise on monomer repolymerization in 100% recycled PET, and Deloitte on the environmental performance analysis of the process for plastic and textile waste.
The European LIFE funding program is a major grants tool that supports innovative solutions with low environmental impact and a track record of industrial deployment. Carbios' C-ZYME™ technology fully complies with the European Commission's goals.
Faced with the limitations of thermomechanical recycling processes, Carbios' approach is unique in that it creates value for plastic and textile waste by providing 100% recycling of all types of PET waste without loss of quality. Carbios is committed to a truly circular economy model across the whole value chain of the plastics and textiles life cycle. 
The grant will help fund the development of trials on plastic and textile waste at the demonstration plant, which will help confirm the process's scale-up and lead to the commercialization of the technology through licensing. This one-of-a-kind method will fulfil both the European Union's regulatory requirements and the ambitions of large companies that have announced significant commitments to sustainable materials.

Valbiotis: preclinical results for TOTUM•070 in hypercholesterolemia, selected and presented at the American Heart Association (AHA) annual meeting

TOTUM.070 is an innovative active substance based on a combination of 5 plant extracts, designed to reduce LDL cholesterol, a cardiovascular risk factor and the primary cause of atherosclerosis. It is developed for people with mild to moderate, untreated hypercholesterolemia.

Read more

Two in-depth studies on TOTUM.070 conducted jointly by Valbiotis’ preclinical platform and the University of Leiden (Netherlands), have been selected by the annual meeting of the AHA, the leading American learned society in the cardiovascular field.
Results show a dose-dependent reduction of 38 to 47% of "bad" cholesterol* (including LDL cholesterol) by TOTUM.070, as well as a reduction of total cholesterol and blood triglycerides, in two in vivo models predictive of human physiology.

These first data are in favor of a multi-target mode of action of TOTUM.070, with revealed effects on the gut and liver, involving lipid metabolism and inflammation.
These excellent results are very promising for the clinical development of TOTUM.070 in hypercholesterolemia: the Phase II HEART clinical study, which has completed enrolment, will deliver its results in the second quarter of 2022, with LDL cholesterol reduction as the primary endpoint.

Pascal Mayer receives the prestigious breakthrough prize for his massive parallel sequencing technology codecovery.

Pascal Mayer, now head of the Alphanosos company he created in 2014 on the Riom site of the Biopôle Clermont-Limagne, has just received the Breakthrough Prize in the life sciences category, for its co-discovery of a technology developed nearly 25 years ago that revolutionized DNA analysis.

Read more

It is thanks to this technology, the next generation sequencing (NGS) that DNA analyses can now be carried out at high speed and at a significantly reduced cost. One of the keys to his technique is creating clusters of DNA, by cutting up the genome into small pieces, then creating thousands of copies of them and grouping them into islands of sorts.

Assembled together, they can be read simultaneously and more easily by fluorescence.


For example, the sequencing of the first complete human genome was completed in 2003, after ten years and an investment of over $1 billion. Thanks to NGS, also called massive parallel sequencing, the process can now be done overnight at a cost of $1,000.


Massive parallel sequencing is now used on a large scale and around the world to diagnose and treat certain cancers and rare diseases, in forensic investigations, or in sequencing COVID and its variants.


After studying at the University of Strasbourg and completing postdoctoral fellowships in Canada and in France, Mayer tested his idea for the first time in Geneva, in the research center of a pharmaceutical company where he then worked.

The technology was later acquired by a start-up founded by Balasubramanian and Klenerman, two British scientists working on the same problem.  Their company was eventually bought by the US genetic research company Illumina, the global leader in genetic sequencing, which has 17,000 sequencing machines around the globe.


The American prize, launched by Silicon Valley entrepreneurs to recognize the latest scientific advances, carries an award of a hefty $3 million,



The American prize, which rewards breakthroughs in basic research, is endowed with $3 million shared between the three co-creators.

Pascal Mayer intends to reinvest part of it to support the development of projects carried out by his company Alphanosos. After the «Next Generation Sequencing» (NGS), it develops, thanks to its rapid discovery platform guided by its owner AI, «Next Generation Therapeutics» against pathogens, in particular those involved in eczema, acne, psoriasis, and gonorrhea, and the COVID virus, with promising results in mice.


Valbiotis obtains patent for its active substance TOTUM-63 in China.

Valbiotis has obtained a patent in China for TOTUM-63. This patent protects is issued by the China National Intellectual Property Administration (CNIPA), and protects the composition and use of TOTUM-63 for the prevention of type 2 diabetes and metabolic diseases until 2035.

Read more

China, whose economic development has been accompanied by an explosion of metabolic disorders since the 2000s, is now believed to have the largest prediabetic population in the world, with an estimated 390 million people (35% of the adult population).

Valbiotis is achieving its global protection strategy, with the TOTUM-63 patent now acquired in nearly 50 countries including Europe, the United States and China, to market this active substance worldwide in partnership with Nestlé Health Science.

Carbios and Michelin on their way to 100% sustainable tires

Michelin has successfully validated the use of Carbios’ enzymatic recycling technology for PET plastic waste in its tires, a new step towards 100% sustainable tires.

Read more

Michelin has successfully tested and applied Carbios’ enzymatic recycling process for PET plastic waste, in order to create a high tenacity tire fibre that meets the tire-giant’s technical requirements.

Carbios’ enzymatic recycling process uses an enzyme capable of depolymerizing the PET contained in various plastics or textiles (bottles, trays, polyester clothing, etc.). This innovation allows infinite recycling of all types of PET waste. It also allows the production of 100% recycled and 100% recyclable PET products, with the same quality as if they were produced with virgin PET.

The application of PET enzymatic recycling in car tires is a world first.

Conventional thermomechanical recycling processes for complex plastics do not achieve the PET high-performance grade required for pneumatic applications. However, the monomers resulting from Carbios’ process, which used colored and opaque plastic waste such as bottles, once repolymerized in PET, made it possible to obtain a high tenacity fibre meeting Michelin’s tire requirements.

The technical fibre obtained is of the same quality as the one from virgin PET, processed with the same prototype installations. This high tenacity polyester is particularly suitable for tires, due to its breakage resistance, toughness, and thermal stability.

Carbios’ enzymatic recycling process therefore enables Michelin to get one step closer to its sustainable ambitions, and contributes to the entry of tires into a true circular economy. Michelin is committed to achieving 40% sustainable materials (of renewable or recycled origin) by 2030 and 100% by 2050. This should ultimately represents nearly 3 billion plastic bottles per year that could be recycled into technical fibres for use in the company’s tires.

With its extension project supported by France Relance, the Icare group strengthens its development ambitions.

Over the past 25 years, the Icare Group, an expert in contamination control at the service of industrial health, has meshed the entire French territory and gained an international standing. Today, it invests more than 2 million euros on the Biopôle Clermont-Limagne in Saint-Beauzire to provide its headquarters with an additional 1,300 m2, an extension that allows it to strengthen its development strategy.

Read more

The extension project was hampered in 2020 by the health crisis. The company was then dedicated to preserving jobs, recruiting and adapting its business, becoming the European reference for the certification of surgical masks.

In 2021, supported by an 800,000 euro grant from the Recovery Plan - Support for Industrial Investment in Territories Initiated by the State, the project was relaunched and will be finished in mid-2022.

In Saint-Beauzire, Icare already employs 120 people out of the group’s 200.
Thanks to this investment, the company is expanding its laboratory workspaces and modernizing its production. The group intends to continue to hire in all its fields of activity and contribute to the relocation of production resources in France in the field of industrial health.

The project is also part of an environmental approach. It will reduce the energy consumption of the Saint-Beauzire site by 30%.

METabolic EXplorer negociates with Ajinomoto to acquire Europe’s largest site producing amino acids by fermentation

METabolic EXplorer has entered into negotiations with Ajinomoto Co., Inc. with a view to acquiring its European subsidiary Ajinomoto Animal Nutrition Europe (AANE), Europe’s top producer of amino acids by fermentation for animal nutrition. 

Read more

The new METEX organization (including AANE and METEX NØØVISTA) would comprise 450 employees with annual production capacities of more than 100 kt at Amiens and 6 kt of PDO (1-3 propanediol) and BA (butyric acid) at Carling Saint-Avold.

With the Ajinomoto Animal Nutrition Europe site, METEX acquires the leading European site for the production of amino acids by fermentation, a highly automated manufacturing infrastructure equipped with the latest technologies in fermentation and extraction/purification and a unique know-how in the field of bioproduction powered by a team with extensive skills and experience from applicative R&D up to fermentation processes using 500 m³ fermenters. METEX also acquires sales force with expertise in the animal nutrition market with a top-notch distribution network and a comprehensive technology portfolio under exclusive licences for the essential amino acids for animal nutrition in the European, African and Middle Eastern territories.

The new METEX organisation would incorporate the Group’s well-established upstream R&D and pre-industrial demonstration expertise and, downstream, the manufacturing infrastructure, sales force and distribution networks of AANE and METEX NØØVISTA.

METEX would bring its expertise in the development of bioprocesses to manufacture functional ingredients in high-value-added markets. Having invested over €90m in R&D since its inception, METEX has acknowledged expertise in developing patented fermentation strains and managing processes at the pre-industrial stage.

The plan is a major step forward for METEX in its goal to become a leader in the global market for naturally derived functional ingredients made through fermentation.


METabolic EXplorer has obtained a €9.6- million French government subsidy in support of its investment in an industrial plant for the production of glycolic acid in France.

After producing the first batches of glycolic acid of natural origin with its industrial demonstrator, METEX is implementing its industrial plan for the production with its own facilities of the first bio-based glycolic acid, supported by the French government with a subsidy of nearly €10 million as part as its stimulus plan for strategic activities.

Read more

This project, whose cost is currently estimated at between €40 million and €45 million, has two phases: the studies and developments necessary to make investment decisions in late 2021 and the investment in the construction and commissioning of the production unit with a capacity in its initial phase of 2,500t/year.

The development activities that will be carried out in the glycolic acid project in 2021 have two objectives: a decision at the end of 2021 concerning the industrialization of the technology to target the cosmetics market and the preparation of industrial partnerships for polymer applications, particularly in the medical industry, a high value-added market.

This €9.6 million in funding from the French government will go toward the construction by METEX of the first production unit in France and Europe. Glycolic acid is currently produced exclusively by American and Asian petrochemical manufacturers. This industrial plant, which will employ fermentation technology, will be the first in the world to produce bio-based glycolic acid. This subsidy is being provided in a French government program to support investment in the transformation of agricultural resources and the bio-production of basic industrial inputs, two strategic priorities of the government's industrial stimulus policy.

Alphanosos deploys its technology on the Covid19 front

Alphanosos is a French Green-Health DeepTech company, specialized in the research of new innovative treatments. The company has developed proprietary artificial intelligence to elaborate, from aqueous botanical extracts, highly effective products against viruses, bacteria or cancer cells. This innovative approach tackles the most resistant pathologies thanks to its active ingredients, capable of unbalancing and eliminating the pathogenic target without impairing the host.

Read more

Artificial intelligence makes it possible to identify among 1040 mixing possibilities of 1000 plants preselected for their safety, the one mix that will act against the pathogen target but not against the host organism. The target is thus subjected to massive perturbations by a large number of highly diverse molecules, each at low dosage but acting together to empirically obtain the desired effect on the target organism. This is the principle of multitherapy “raised to the power of 10”.

This approach has already demonstrated its effectiveness with in vitro experiments on Staphylococcus aureus, which is multi-resistant to powerful antibiotics. This activity has been confirmed with in vivo tests by achieving 100% survival of treated mice versus 100% mortality of untreated mice after induced sepsis.

Today, Alphanosos discovered an effective product against SARS-Cov2. Without toxic risk, affordable, easy to manufacture and supported by convincing In Vitro and on mice In Vivo research results, this product brings a breakthrough innovation in the fight against COVID19.
Developed from common edible plants, the non-toxic and easy-to-produce W17P4690 will enter animal testing mid-February. A clinical study is envisaged for March for a product available in May.
The company Alphanosos is now looking for support to finalize its development and accelerate its contribution to controlling the COVID19 crisis.  


Discover BIOLIFE ENTERPRISES special Biopôle Clermont-Limagne

With 100 pages devoted exclusively to life sciences, Biolife Enterprises magazine is aimed at a curious audience interested in social and scientific issues. 

Read more

It aims to link business innovation to societal and environmental issues and to decipher the positive impact of life sciences on today’s world. Among them, ANS Biotech, Aptys Pharmaceuticals, Biofilm Control, Greentech, Greencell, Icare, Limagrain, METabolic Explorer  and Solunature. These companies of all sizes are active in a wide variety of fields, but they share the common thread of innovation and the constant search for solutions to current problems, in a world where societal, environmental and health challenges have never been higher.

The magazine Biolife enterprises is already available in print and on the web from 1st February on

METEX produces with its industrial demonstrator the first Glycolic Acid of natural origin

METabolic EXplorer has obtained, at the demonstrator scale, the first biosourced samples of Glycolic Acid intended primarily for cosmetic markets. With this first glycolic acid of natural origin, the portfolio of METEX expands a new process with pre-industrial maturity for a premium product in a market in search of naturalness.

Read more

Today, Glycolic Acid is exclusively produced by petrochemical processes. METEX is the first company in the world to validate, at the industrial demonstrator stage, an alternative and patented process based on fermentation. It is a major differentiating factor for addressing cosmetic markets as a priority.
The characterization of this first AG of natural origin cosmetic grade will allow the validation of its performance in the formulation of dermo-cosmetic products. This step will also make it possible to freeze the process for the manufacture of batches which will be used to sample, in the first half of 2021, the market participants interested in substituting, in their formulas, the petrochemical AG with the same active ingredient of natural origin.

The Glycolic Acid is a reference active anti-aging used in cosmetics and is also a precursor of 2 biodegradable polymers: PGA (Poly Glycolic Acid) and PLGA (Poly Lactic co-Glycolic Acid). The biodegradability of the polymer is determined by the proportion of glycolic acid incorporated. This property is valued today in medical applications for the manufacture of self-absorbing surgical yarns and tomorrow for the manufacture of 100% bio-sourced plastics with shortened life cycles.

Taken together, the global glycolic acid market is valued at more than €130 million in 20201. METEX is targeting a market whose growth, estimated at between 5 and 10%, could accelerate with a first biosourced solution. New applications, particularly in biodegradable bioplastics, represent additional growth potential.
Already, METabolic EXplorer pursues two objectives: a clean industrialization of technology at the end of 2021 to the cosmetics market, and the preparation of industrial partnerships for polymer applications in the first place for the high value-added medical sector.

Carbios produces first clear plastic bottles from textile waste

This is a major innovation for the valorisation of 42 million tons of polyesters textiles produced annually: the Auvergne green chemistry company Carbios announced «a world first» in the recycling of plastic with the development of a process to produce bottles containing 100% recycled Purified Terephthalic Acid (rPTA) from textile waste that contains a high PET content.

Read more

Currently, mechanical recycling technologies do not enable clothing waste to be recycled efficiently. The few textiles that can be reused, are incorporated into lower quality applications such as padding, insulators or rags. This process is called “downcycling”.

In contrast, the breakthrough developed by Carbios enables polyester textile fibers to be “upcycled” in a high quality grade of PET suitable for the production of clear bottles.

The transparent bottles thus produced have identical properties as those made from virgin PET. This major innovation allows to expand the sources of supply which, until now, consisted primarily of PET plastic waste.

This result demonstrates the extent of Carbios technology’s possibilities that allows the production of transparent bottles from polyester textile waste or from post-consumer colored bottles. This works both ways and and it is also possible to make a t-shirt from bottles or disposable food trays. Indeed, Carbios has succeeded in producing PET fibers for textile applications with 100% rPTA, from enzymatically recycled PET plastic waste.

These major outcomes were achieved as part of the CE-PET (Circular Economy PET) research project, of which Carbios is the lead alongside its partner TWB (Toulouse White Biotechnology). This project was financed by ADEME (the French Environment and Energy Management Agency).

Carbios’ process enables low-value waste to be recovered and to have a new life in more challenging applications – in short, it facilitates infinite recycling of PET-based plastics and textiles. This innovative enzymatic waste recycling technology is fully in line with European objectives of creating a circular economy and strengthening environmental protection.

Aptys Pharmaceuticals receives €750,000 from BPI France for its Metapain project.

In September 2020, Aptys Pharmaceuticals received a €750,000 repayable grant from BPIFRANCE FINANCEMENT to support the development of its pain medicine.

Read more

Named Metapain, the project is the result of a collaboration initiated in January 2017 between APTYS Pharmaceuticals and CDMO UNITHER Pharmaceuticals, world leader in the production of sterile single-dose drugs.
The Metapain project aims to market a tablet based on the combination of two non-opioid analgesic molecules. This product represents a new alternative for the treatment of moderate to severe pain. It aims to fill the gap left by the withdrawal of Di-Antalvic in the arsenal of pain treatment. After receiving favourable scientific advice from the EMA on their programme, the partners are preparing an international phase 3 study, which should start at the end of the year.

CARBOGEN AMCIS announces major investments of which more than 45 million euros on the Biopôle Clermont-Limagne.

Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient and drug products manufacturing company, announced new expansion plans in Switzerland and France. 

Read more

The company is planning a major expansion project of its French site that will increase manufacturing capacity to better meet the expectations of the current market and its customers. This new facility will be dedicated to the manufacture of injectable products, both for the supply of clinical and commercial batches and will be able to treat complex formulations that can implement a wide range of different types of active ingredients, both chemical and biological.

Located on a plot of over 14,000 m2, this two-storey building with a surface area of 9,500 m2 will include a large area of research and development and quality control laboratories, while production will be ensured by two aseptic filling lines under state-of-the-art insulator. The building will also have additional space for future expansion.

CARBOGEN AMCIS, which currently employs around 40 people in the Puy-de-Dôme, plans to open between 60 and 70 new positions.

This expansion project is part of a global strategic growth plan of CARBOGEN AMCIS which is also investing in the creation of a new production plant in Switzerland.


Carbios begins construction on industrial demonstration plant in final step to commercializing its pet recycling technology.

Carbios, a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announced the launch of the construction of its industrial demonstration plant for the enzymatic recycling of PET plastic.

Read more

The demonstration plant is located near Lyon, in France’s Chemistry Valley.

Carbios is supported and advised by TechnipFMC for the engineering and construction of this demonstration plant.

The objective of the plant is to generate technical data that will allow Carbios to define the main parameters for each step of the enzymatic recycling process, on a sufficient scale to be able to plan the operation of future industrial units. The first phase of the system operations is scheduled to launch in the second quarter of 2021. This will allow Carbios to establish the complete engineering documents for the process, for the construction and implementation of the first industrial unit for a licensee (estimated capacity between 50 and 100 kt per year).


The demonstration plant will validate the technical, environmental, and economic performance of Carbios’ innovative technology. It will also produce batches of monomers for technical and regulatory validation of recycled PET by future licensees.

A new laboratory to prevent inflammatory diseases associated with overweight and obesity.

Greentech, a world leader in plant biotechnology that produces ingredients for the cosmetics, pharmacy and nutrition sectors, recently teamed up with the ECREIN team of the Human Nutrition Unit at the Université Clermont Auvergne (UCA) and INRAE, known for its expertise in the study of immunocompetent cells.

Read more

These two partners have joined forces to create a joint public-private laboratory (Labcom) funded by the Agence Nationale de la Recherche (ANR). Called “Phytoprob’Inov” (phytoprobiotics, obesity, inflammation and innovation), the latter will develop new phytoprobiotics (plant and bacterial ingredients) for medical and cosmetic purposes that will target overweight and obesity associated with an inflammatory state, a major public health problem that currently does not have such a therapeutic response.

Phytoprob'Inov will be operational in the fall of 2020 and will mobilize about twenty people. It is part of the “mobility and health” component of the CAP 20-25 I-Site. This project, led by the UCA and a consortium of 20 partners (higher education and research, communities, companies, healthcare institutions, etc.), is one of the 18 initiatives of excellence recognized at the national level among dozens of applications, financed by the Forward Investment Programme II and implemented by the ANR.

With Soludiag and Nanosolution, Aptys Pharmaservices evaluates and improves the solubility and availability of active ingredients.

Aptys Pharmaservices, a subsidiary of Aptys Pharmaceuticals, has specialized as an expert CRO in galenic formulation, analytical development and quality control in a Good Manufacturing Practices (GMP) environment.

Read more

With its ability to innovate and solve formulation problems, Aptys Pharamaservices now offers two innovative approaches to solving the solubility and bioavailability problems of active ingredients.

Many biotech and pharmaceutical companies are facing problems of solubility of their candidate molecules. It is a problem in terms of their bioavailability, which could be summarized as the molecule’s ability to reach its pharmacological target.

Also, in the early stage of development, companies have small quantities of product, preventing the establishment of conventional protocols.

To address this double problem, Aptys Pharmaservices offers two technologies, Soludiag and Nanosolution.

Soludiag is a fast, sequenced and low-matter-consuming solution. It makes it possible to evaluate the solubility of the molecule in about twenty conditions of solvents and co-solvents compatible with a pre-clinical and clinical use but also to find conditions to formulate these molecules and make them more bioavailable.

Nanosolution is a technique that optimizes the conditions for particle size reduction, thus increasing the bioavailability of insoluble molecules. Nanosolution has the advantage of being able to test many compositions in a single step and using little material.

Bio-based products : AFYREN and the AFTER-BIOCHEM European consortium obtain a funding of 20 million euros.

AFYREN has successfully gathered 12 key bioeconomy players around a new European project to develop the first of its kind flagship biorefinery in France.

Read more

AFYREN meets a growing need among businesses and industries to reduce the use of petroleum-based products in their production lines. It can be achieved by producing biomolecules derived from non-food biomass, largely used in the sectors of cosmetics, flavours and fragrances, human and animal nutrition and fine chemicals. This production of renewable carbon, within a circular economy, is achieved through worldwide patented fermentation technology resulting from 10 years of research.


The AFTER-BIOCHEM (Anaerobic Fermentation & EsteRification of BIOmass for producing fine CHEMicals) consortium project aims to create innovative and more sustainable value chains from non-food biomass feedstock, by producing multiple high added-value products.

Applications will target various markets such as fragrances & flavorings, personal care, food & feed, pharmaceuticals, and industrial chemicals.


AFTER-BIOCHEM is financed with 20 million euros from the Bio-Based Industries Joint Undertaking (BBI-JU). BBI-JU is the a public-private partnership between the European Union and the Bio-based Industries Consortium (BIC), an organization that connects large and small / medium enterprises, research institutions, universities and public and private bodies at European level involved in the development of the circular bio-economy.


The project will build an all-in-one and first of its kind flagship biorefinery within the chemical platform sited at Carling-Saint-Avold (in the region GrandEst, France). AFTER-BIOCHEM’s operational coordination and plant management will rely on AFYREN NEOXY, AFYREN affiliate company, co-invested with SPI fund from Bpifrance.




3  SME, 8 large companies and 1 innovation cluster, the d’AFTER-BIOCHEM partners come from 5 European countries pôle d'innovation.

More information: Afyren Press Release


ANS Biotech launches a new neuropathic pain model.

In France, the total number of new cancer cases is estimated at about 400,000 each year.

Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%).


Read more

Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases/year in France) but its use is limited by a cumulative and chronic hematotoxicity, nephrotoxicity and neurotoxicity. The latter, particularly debilitating, is difficult to assess and treatments remain empirical and ineffective. Clinical signs include dysesthesia (pain caused by stimulus or contact) and paresthesia (tingling, burning) in the distal extremities, spontaneous pain and loss of sensation. 

The limitation of current iatrogenic pain treatments encourage companies like ANS Biotech to develop relevant preclinical models.
In the particular case of oxaliplatin, chronic peripheral sensory neuropathy is induced by repeated injections of oxaliplatin (4 mg/kg) twice a week during 3 consecutive weeks. 


Specialized in Services and R&D in pharmacology of pain, ANS Biotech has developed a a model of hypersensitivity to cold induced by Oxaliplatin.

This model enables exploring significant behavioural nociceptive signs and is consistent with clinical symptoms increasing progressively in duration and severity with repetition of treatment-cycles. It is useful to evaluate the antalgic effects of new compounds provided by its customers on oxaliplatin-induced chronic painful symptoms.

The Icare laboratory evaluates the effectiveness of masks and filter materials.

The Icare laboratory controls and validates the safety of medicines and medical devices (hydroalcoholic gels, surgical sets, dressings, syringes, implants...) used in health centers such as pharmaceutical industries, hospitals, clinics, doctors' offices, to ensure their placing on the market in accordance with the regulations in force.

Read more

In the context of the current health crisis, the Icare laboratory has developed a fast and reliable test to evaluate the performance of surgical masks and filter masks.
This test, which adapts to the different types of masks (FFP2 and surgical), demonstrates the protection to the projections as well as the protection of the wearer vis-à-vis a contaminated environment.

Filtration efficiency is measured by measuring the penetration of a polydisperse aerosol into the filter media. Six different particle sizes are measured to assess both the protection of the wearer’s immediate environment through the limitation of transmission of infectious agents from the wearer’s nose and mouth (role of a surgical mask), and the protection of the wearer against an environment contaminated by infectious particles (role of a filter mask against FFP2 or FFP3 type particles).

In accordance with NF EN 14683 (2019) Medical Masks – Requirements and Test Method, the 3 µm particle size was selected to assess the environmental protection performance. The expected level is a filtration efficiency greater than or equal to 98%.

In accordance with the standard NF EN 149+A1 (2009) Respirators- Particulate filter half-masks – Requirements, tests, marking, the particle size of 0.3 µm was chosen to assess the protection performance of the wearer. The expected level is a filtration efficiency greater than or equal to 99%.

The test is performed in only 3 days and the simultaneous measurement allows in a single test to measure the effectiveness of protection in both directions.

CARBIOS announced the publication of an article on its enzymatic recycling technology in the prestigious scientific journal Nature.

CARBIOS  announced the publication of an article in the prestigious scientific journal Nature, entitled “An engineered PET-depolymerase to break down and recycle plastic bottles”, a recognition of the quality of the research led by CARBIOS and TBI laboratory scientists in developing a PET recycling enzyme and a revolutionary process.

Read more

The article is  co-authored by scientists at Carbios and at the Company’s renowned academic partner, the Toulouse Biotechnology Institute1 (TBI). 

The article describes the development of a novel enzyme, which can biologically depolymerize all polyethylene terephthalate (PET) plastic waste, followed by an extremely efficient recycling into new bottles. PET is the most common thermoplastic polymer and is used to manufacture bottles, polyester clothing fibers, food containers, and various thermoformed packaging and components. Carbios’ recycling process, the first of its kind, initiates a real transition to a circular economy and can better prevent plastic pollution from harming our oceans and planet. This innovative technology also paves the way for recycling PET fibers, another major challenge in guaranteeing a clean and protected environment for future generations. 

For Carbios and TBI, this is a real honor to be recognized by one of the most highly respected scientific journals in the world.

METEX NØØVISTA and ALINOVA announce an agreement for the marketing in France of the first bio-based butyric acid for animal nutrition.

METEX NØØVISTA, the industrial subsidiary of METABOLIC EXPLORER and ALINOVA (a Brittany-based joint-venture between AxiHolding and AXEREAL) today announce an agreement for the marketing in France of the first 100% bio-based butyric acid for animal nutrition made in France.

Read more

METEX NØØVISTA, the industrial subsidiary of METABOLIC EXPLORER, a cleantech biochemical company that develops and industrializes competitive and sustainable fermentation processes offering alternatives to petrochemistry for the production and marketing of functional ingredients, and ALINOVA (a Brittany-based joint-venture between AxiHolding and AXEREAL, which is a leading animal feed group and an expert in the formulation of functional ingredients of natural origin for animal nutrition), today announce an agreement for the marketing in France of the first 100% bio-based butyric acid for animal nutrition made in France.

This partnership will enable ALINOVA to grow its portfolio of technical, performance-enhancing products to meet its customers’ needs for natural and sustainable ingredients. This agreement resulting from the two partners’ combined efforts will allow METEX NØØVISTA to benefit from ALINOVA’s outstanding network and services and thereby offer ingredients based on the first butyric acid of natural origin to French animal feed manufacturers.

With this exclusive agreement for the territory of France, ALINOVA’s scientific expertise and network coverage will be combined with METEX’s expertise in the production by fermentation of functional ingredients to deliver the first butyric acid of natural origin for animal nutrition made in France.
Butyric acid and its derivatives (sodium butyrate) are multifunctional ingredients with proven and recognised benefits for animal growth and health. They act on the intestinal functions of animals by improving nutrient absorption and strengthening the defenses of epithelial cells.

It will be produced at METEX NØØVISTA’s Carling-Saint-Avold site now under construction in Lorraine. This facility will have an initial production capacity of 1,000 tonnes of butyric acid to respond to the growing demand in the animal nutrition market. Production of this first European plant is scheduled to start at the end of 2020.


BIOFILM CONTROL expands its analytical service activity in microbiology.

In 2020, BIOFILM CONTROL develops its know-how and provides its expertise in the areas of cosmetics, agri-food and hygiene, etc.

Read more

Biofilm Control’s offer is aimed more specifically at manufacturers of assets or cosmetics products, manufacturers of medical devices, cleaning solutions, medical equipment or food suppliers.
R&D service provider, Biofilm Control can, for example, take charge of:
    - Objectivation projects, for your cosmetic assets by evaluating their activity on the skin microbiota.
    - Problems with contamination of medical devices by validating their cleaning or decontamination in a preventive manner.
    - Development of antibiofilm hygiene strategy (cleaning).
    - Screening of nutraceuticals for action on intestinal microbiota. 
Biofilm Control can also provide consulting and training sessions (any subject related to contamination). 

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance for prediabetics.

VALBIOTIS, a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics.

Read more

Nestlé  Health Science’s global reach and metabolic diseases focus expected to support TOTUM-63 development and global commercialization.
Strategic  partnership  secures  funding  for  the  latest  clinical  development  phase  until  the obtention of health claims from American and European Authorities.
Deal is structured around an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million and tiered royalties on net sales.
Agreement also includes TOTUM-63 supply to Nestlé Health Science representing an additional source of revenue.
As part of the agreement, a joint steering committee comprised of representatives of both companies will oversee clinical development, regulatory matters, supply and commercialization.

Industrial Biotech enters FT120 with AFYREN

Afyren, flagship of the French Biotech that has created a breakthrough green chemistry innovation, announced its nomination in the French Tech 120 program carried out by The French Tech Mission and BPI France. 

Read more

Among the 83 French startups chosen for this program, from among 300 promising start-ups at national and territorial level, it was selected for its high potential, both for its €21 million fund-raising in January 2019 and for its hyper-growth.
While everyday consumer products are still too largely composed of molecules derived from petroleum, AFYREN offers manufacturers bio-sourced substitute molecules, thanks to its environmentally friendly technology based on natural micro-organisms.
After the Next 40 unveiled in September 2019, the French Tech 120’s mission is to help these startups by meeting their priority needs, in connection with a network of French Tech correspondents present in the French partner institutions. And to help them through international influence or communication operations.


APTYS PHARMACEUTICALS, a laboratory specialized in galenical formulation, announces that it has completed a € 2.1 million fundraiser led by NDLS Conseil from the Meeschaert family office.

Founded in 2002 by François Boutignon following the signing of agreements with the Université d’Auvergne to obtain exploitation rights for technological patents of pharmaceutical formulation, APTYS Pharmaceuticals aims to develop an innovative pain treatment in collaboration with UNITHER Pharmaceuticals.

Read more

While the withdrawal of dextropropoxyphene in 2010 caused a flaw in the therapeutic pain arsenal in Europe, the use of opioids has significantly increased in recent decades.

Initially, APTYS Pharmaceuticals decided to focus its efforts on the development of a treatment for moderate to severe pain (level II) based on the synergy of two non-opioid analgesics, thus reducing the risks of abuse and opioid dependence. The company has already entered into a strategic partnership with a major player in the pharmaceutical industry in France, UNITHER Pharmaceuticals.

This fundraising will allow APTYS to strengthen its team, and the 2 partners to finalize the development of this new treatment up to the AMM, and then to offer it to a pharmaceutical laboratory under a license agreement or sale.

Carbios and TBI (Toulouse Biotechnology Institute) set up an enzyme engineering research center of international scale on plastic recycling and biosynthesis.

CARBIOS, a French green chemistry company based in Clermont-Ferrand, announced today a strategic alliance with INSA Toulouse through the internationally recognized laboratory “Toulouse Biotechnology Institute”, a mixed research unit INSA Toulouse, INRA, CNRS.

Read more

Carbios is establishing, with TBI, a research center for enzymatic engineering, which will be focused on plastic recycling and biosynthesis. This laboratory, unprecedented in the world of enzymatic engineering and dedicated to plastic applications, will be inaugurated on January 28, 2020, at INSA Toulouse.

The cooperative laboratory, called “PoPLaB” (Plastic Polymers and Biotechnologies), is the culmination of seven years of scientific collaboration. This collective work led in 2016, to the creation of Carbiolice, Carbios’ subsidiary, dedicated to PLA biodegradation and in 2019, to the first 100% PET plastic bottles produced through Carbios’ biorecycling process.

Carbios also announced that it is becoming a member of the INSA Toulouse Foundation, an initiative that strengthens the links between the two entities. The Foundation makes a significant contribution to the training and international openness of students and scientific executives specifically with the creation of a program “Biotechnologies and Environment”.

The ICARE Group announces the acquisition of the companies LEMI and PHYCHER Bio Development from the CASSOUS Group.

With this new acquisition, the Icare Group confirms its strategy of external growth and development of its service offer in a medical field deemed to be of strategic importance, given the evidence of the complementarity of the three structures to meet the needs of its clients and regulatory developments, in France and International.

Read more

ICARE is an international group with 4 specialized subsidiaries: Laboratoire ICARE, ICARE Validation, Laboratoire ICARE SWITZERLAND (in Switzerland) and MEDLAB (in Brazil). Service provider, expert in contamination control for industrial health stakeholders, its main activity is to ensure the safety of health products in compliance with regulations.
The group offers : 
• Life sciences (Medical Device and pharma Testing) : laboratory analysis , microbiology,  physical and chemical test results , characterization, tests on packaging…
• Validation Qualification :  Process, production and laboratory equipment, software, shipping validation, , assistance in the formulation of strategies, drafting of protocols and reports, test performance…
• Technical assistance : assistance and training programs related to regulatory requirements, technical assistance, regulatory assistance and monitoring …
• R&D: custom development of innovative processes and products, tailored test facility, optimization…
The laboratories LEMI and PHYCHER Bio développement round out this offer via the following services:
• biological Risk Assessment (BRA) 
• cytotoxicity  according to ISO 10993-5 
• Acute toxicity in the mouse  according to ISO 10993-11 
• irritation in rabbits according to ISO 10993-10 
• sensitizing reaction in guinea pigs according to ISO 10993-10… 
The ensemble ICARE, LEMI and PHYCHER Bio développement provides a technical answer to all biocompatibility tests, in particular according to ISO 10993.
The mission of ICARE through its services enables "Partner" clients to have the assurance that their device or manufactured product are placed on the market in compliance with regulatory and normative requirements.
VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA® before 31 July 2019

VALBIOTIS is a French Research & Development company located at 3 sites in France including the Biopole Clermont-Limagne Riom site

Read more

Its products are made for major players in the healthcare sector, in the field of metabolic diseases. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. 

VALEDIA® is the the most advanced product in the VALBIOTIS pipeline. The launch of VALEDIA® is planned for 2021, with a health claim for reducing the risk of type 2 diabetes.  
VALEDIA® intend to be the first natural and clinically proven solution specifically designed for prediabetics. VALEDIA® contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of type 2 diabetes. 

TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. 

Today, VALEDIA® announces  the  completion  of  the  international  Phase  IIA  clinical  study  evaluating  VALEDIA®  in  prediabetic subjects. VALBIOTIS will present the results of this study before 31 July 2019. 


The international Phase IIA, multicentric study evaluates the efficacy of TOTUM-63, the active ingredient of VALEDIA, reducing one or more of the 3 risk factors for type 2 diabetes, from the 3 criteria chosen by the Food and Drug Administration2  to obtain a healthclaim: insulin resistance, moderate fasting hyperglycemia and glucose intolerance.

In addition to these prediabetes results, the study will evaluate other physiological parameters, including, for example, triglyceride regulation or intestinal microbiota composition.  This additional data will help confirm the potential of VALEDIA® for other applications.

Aptys Pharmaservices started its operations in the frame of its GMP status

Founded in 2018, APTYS Pharmaservices is a subsidiary of Aptys Pharmaceuticals. APTYS Pharmaservices is a GMP CRO specializing in formulation design, analytical development and validation, quality control and ICH stability.


Read more

Following the complete transfer of the GMP activity and the approval of the French agency ANSM, APTYS Pharmaservices launched its pharmaceutical activities, carrying out quality control operations in partnership with the CMO Europhartech (
In April, the WHO also confirmed, following its inspection, the qualification of Aptys Pharmaservices for quality control activities.

Carbios and L’Oréal announce a major partnership with Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe.

Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined the consortium previously founded by Carbios and L’Oréal, a partnership between worldwide leaders that aims to accelerate the recyclability of PET by using the Carbios technology.

Read more

The Carbios biological approach can handle all forms of PET plastics (clear, colored, opaque and multilayer) and polyester fibers. The process requires limited heat and no pressure or solvents, which improves its environmental impact, and also provides a competitive solution to increase global plastic recycling rates.

This sustainable and responsible technology creates a circular economy from used plastics and fibers. Carbios recently achieved a world first using its enzymatic technology to create PET bottles from 100% recycled plastics.
The Consortium partners’ ambition is to bring Carbios’ PET-enhanced recycling technology to the market and increase the availability of high-quality recycled plastics to fulfill their sustainability commitments. The collaboration includes technical milestones and support for the efficient supply of consumer-grade, 100% recycled PET plastics for global markets.

StrainChem has just taken a decisive step towards an environmentally friendly peptide synthesis methodology.

The company announced the development of its SPPLS technology operating without protecting groups.  

Read more

StrainChem, an organic chemistry company based on the Biopôle Clermont-Limagne, announced that it has developed a new peptide access technology.

Peptides, chains of amino acids, are molecules with a great number of pharmacological properties and for which cancer, metabolic diseases or diseases of the central nervous system are therapeutic fields in strong demand.

Traditionally, chemists use protecting groups to prepare these molecules of interest. However, their defects are to lengthen the time needed for synthesis, while being costly and polluting.

Free of these protecting groups, the SPPLS technology (StrainChem Liquid Phase Peptide Synthesis) developed by StrainChem offers a real break with a faster, more economical and, above all, more environmentally friendly synthesis. The environmental quality of the process is also due to the fact that the key elements of the technology are recyclable.

StrainChem is already in discussions with financial and industrial partners to exploit this discovery and aims to move its SPPLS technology to the industrial stage within the next 5 years.

Since its creation, StrainChem has been supported by the Busi Incubator, BpiFrance and the Auvergne-Rhône-Alpes Region.


Green chemistry: AFYREN and Bpifrance, via its SPI industrial projects fund, are jointly investing 50 million euros in the industrial joint-venture AFYREN NEOXY.

First industrial subsidiary of AFYREN, AFYREN NEOXY will be focused on producing, using co-products from the sugar industry, 100-pc bio-sourced organic acids that can be used in multiple applications, from cosmetics to flavors and fragrances, human and animal nutrition, and even fine chemicals.  


Read more

The new plant will be based on the CHEMESIS platform in Carling-St Avold, in Moselle, on a 3-hectare site. It  will notably benefit from industrial synergies with the platform’s major operators, among which Total Petrochemicals France.  

Based on co-products from the sugar industry, this unit will produce a range of seven organic acids (Acetic, Propionic, Butyric, Isobutyric, Valeric, Isovaleric and Caproic) with an initial annual capacity of 16,000 tons. This project is expected to generate 60 new direct jobs by 2021.  

The SPI fund will invest 23 million euros for a 49% stake in AFYREN NEOXY, with AFYREN holding the remaining 51% of its capital.

It is receiving financial support from, among others,Total Développement Régional, the Grand-Est region and the Saint-Avold Synergie metropolitan area.

Award ceremony : the New Deal Biotech rewards 6 projects

The New Deal Biotech award ceremony took place on Thursday 21 February at the Biopôle Clermont-Limagne in Saint-Beauzire. The managers of 6 start-up projects received a grant of 12,000 €, an equipped laboratory and a customized support during one year. 

Read more

The New Deal is a support system designed by the Auvergne, which allows entrepreneurs to develop their professional project in the best conditions on its territory.


Launched last October, the second edition of the New Deal Biotech rewards 6 projects and their carriers, offering them a laboratory located in the Biopôle Clermont-Limagne, a support by the Biopôle team and the Busi Incubator and a 12 000 € grant by MSD France. This program is unique in France. It allows to give bio-entrepreneurs the time and means to apply themselves with total peace of mind to their project during a full year, in an environment dedicated to biotechnology activities.

Award ceremony: the NEW DEAL Biotech rewards 6 projects



Stéphanie HERMITTE develops a new range of natural phytosanitary products as an alternative to chemical pesticides for plant and animal health, especially in the field of beekeeping.

The new company will also offer an expertise system for the diagnostic of bee pathologies. Thus, it intends to contribute to the biodiversity conservation that is essential to the survival of bees having to deal with Colony Collapse Disorder.



Collecting hair among hairdressers, the Clément BALDELLOU and James TAYLOR project will answer to solve environnemental issues. As a circular economy actor, CAPILLUM will be the first company that extracts human keratin and offers a high quality product with applications in the cosmetic and medical fields.



The faecal microbiota transplantation consists in tranfering stols from a healthy donor to a patient-recipient, in order to rebalance his altered intestinal bacterial flora. This therapeutic approach is attracting growing interest.

This treatment that helps in healing intestinal dysfunctions, especially after taking antibiotics, could be more accessible and safer thanks to the preventive health medecine platform that Julien SCANZI, Florent BELON and Stéphane GOBRON intend to create.



Jordan SOARES is an Auvergne-based perfumer who wishes to valorize Auvergne perfume plants and propose perfums and new fragrance materials.

The daffodils and narcissus, has, until now, been very little exploited. They constitute the primary object of the company. The entrepreneur also wishes to re-discover forgotten extraction methods that dispense with solvents with petroleum derivatives.



Frédérique VIEVILLE develops a microfluidic analysis system for controlling all sources of germ contamination dedicated to biotech and pharma.

To date, such systems have been established in the medical field. They should be now developed in the pharmaceutical and biotechnology sectors. Their key advantage are to be lighter, cheap and handy, and to save a substantial time for the duration of the analyses.



Giulia SPINA wishes to design, product and market a new air depollution device with water filter and depolluting plants.

Testing is underway to validate the effectiveness of the system. It should be cheaper than existing systems and more aesthetic, thanks to the showcase of plants that it contains.

A first device will be designed for use in home, and bigger systems, will be developped for communities.



AFYREN raises 21 million euros to move into its industrial development phase

AFYREN, which produces high-value bio-based building blocks to manufacture acids using fermentation technologies, has confirmed the production of bio-based organic acids on a pre-industrial scale for use with multiple applications.

Read more

The company has just completed a 21 million euro round of fundraising, led by Sofinnova Partners and Valquest Partners, bringing on board Supernova, Crédit Agricole Création and Crédit Agricole Centre France alongside its historical shareholders AFY Partners and Sofimac Régions (Sofimac and the Jérémie Innovation 1 and 2 funds).


AFYREN’s exclusive proprietary technology makes it possible to produce organic building blocks, previously obtained almost exclusively from petroleum products, using different types of agro-industry products without competing with the food production chain and without generating waste. Using a circular economy, AFYREN transforms different types of biomass into 7 different organic acids that are 100% biosourced and with between 2 and 6 carbons. Thanks to the organic acids’ levels of purity, without use of GMOs, and their natural characteristics, AFYREN is able to target markets that require very high standards of quality, from cosmetics to flavors and fragrances, human and animal nutrition, and even fine chemicals.


This major capital increase is combined with an already secured program to finance AFYREN’s first plant in France, for which design and development plans are already underway. In line with its established strategy, this 60 million euro financing package will enable AFYREN to launch the commercialization of its seven organic natural acids within the next two years. 

January 2019: Alphanosos starts the commercialization of Effiskin®, the first veterinary hygiene product based around an active elaborated using Artificial Intelligence

Alphanosos is proud to announce the availability of its first non-registered commercial product resulting from its AI based discovery efforts: Effiskin® lotion, a purifying hygiene product adapted to pyoderma prone skins and developed based on human dermo-cosmetic standards for demanding vets and dog owners. It is formulated around Synherbs®16P926, an EffiSkin® exclusivity. Additional veterinary hygiene products will be launched throughout 2019.

Read more


Synherbs®16P926 is a patent pending WECMEP (Water Extract of Complex Mix of Edible Plants) which has been elaborated scientifically using Alphanosos’ genuine Artificial Intelligence based discovery methodologies. It allowed for the first time to discover purifying synergies among many billion edible plant mixes possibilities. This 100% natural active is obtained using processes without chemical solvents and is extremely environment-friendly.


Associated to a natural thickener, Synherbs®16P926 creates a favorable environment on the dog’s skin so that persistent irritation sources can be resolved efficiently and naturally. Effiskin® also contains natural restructuring and moisturizing agents to improve skin hydration (superficial epidermal layers).

Effiskin®’s innocuity has been evaluated under veterinary control and an efficacy study is being initiated with a French veterinary school. User’s testimonies updates are available on our product page and brochure.


This product starts being available through veterinaries, pharmacies and additional pet professionals in different countries, starting with France and Switzerland. Contact us for knowing your nearest distributor at Additional distribution agreements are under discussion and some countries are still available for exclusive distribution.

APTYS Pharmaceuticals announces the creation of its new subsidiary APTYS Pharmaservices.

After more than fifteen years of activity, the company has reached a maturity level which led to the separation of its two historical activities with the creation of a subsidiary, totally and exclusively dedicated to its service activity. 

Read more

Since 2002, APTYS has exercised its galenic formulation activity based on patented technologies and analytical development as a service provider but also internally with the objective of providing licenses to third parties. 

Thus, in 2005, Bioalliance Pharma acquired the Loramyc®/Oravig® rights, an oral bioadhesive form of miconazole for the treatment of oropharyngeal candidiasis. In 2013, Viramal acquired the Testocream® rights, a transdermal form of testosterone, for the treatment of hypogonadism. 

2017 was a significant year as APTYS obtained the pharmaceutical establishment status for its quality control activity. It signed a partnership agreement with Unither Pharaceuticals to develop an innovative product for pain treatment. Such innovation led to a co-funding venture including the Rhône-Alpes Region/FEDER/BPI. 

The year 2018 saw its qualification by the World Health Organization for its quality control activity, and the entry of a new investor into the company's capital to continue funding the pain treatment project.

You wish to develop your project of biotechnology start-up: take part to the New Deal Biotech competition!

The Biopole Clermont-Limagne launches with his partners the second edition of the New Deal Biotech competition, a unique support system dedicated to project leaders in the field of biotechnology.

Read more

During one year, the New Deal Biotech offers to its prize-winners the ideal conditions to create their company: a laboratory within the Biopole, the support by the teams from the Biopole and the BUSI Incubator, as well as a 12000-€ subsidy by MSD France.
Mores information and the application file are available on the website The candidates have until January 10th, 2019 to send their file.

Céréales Vallée and Nutravita: a fusion to become the European leader of preventive/health functional ingredients of plant origin

Announced in September, the marriage between Céréales Vallée and Nutravita will become a reality during the next general meetings of both entities which will be held on December 3rd, 2018.

Read more

Since 2005, Céréales Vallée, specialized in the field crops sector (cereal and oilseed), provides an expertise on the upstream supply and the vegetable production. The Pole of competitiveness integrates public and privates competencies on techno-seeds, on cultural experiment, knowledge of grounds and interactions grounds-microorganisms.


For its part, with a strategy based on the development of scientifically validated nutritional products, the cluster Nutravita offers an added value on the Health Nutrition Prevention market.


The association of both structures will allow to master the know-how from the field to the characterized plant extract. Every network can thus reach new expertise and possible collaborations and new levers of innovation. The members of Nutravita will have access to organized and drawn productions and will benefit from the reputation of the pole of competitiveness. Céréales Vallée will have an additional lever to increase the income of the farmers by the diversification and the valuation of their production.


The new group will provide a different and unique offer on the territory, based on a chain from vegetable production to preclinical and clinical validation of ingredients intended for animal feed, the food industry or pharmaceuticals.

With the arrival of a new financial partner, Aptys Pharmaceuticals strengthens the development of its analgesic

In the last months , the opioids crisis in the US and Europe has demonstrated tolerance and addiction problems caused by analgesic treatments based on opioids. In the treating pain panoply, there is today an acute lack of a potent analgesic drug without these disadvantages.


Read more

Aptys Phamaceuticals, specialized in the development of formulations and analysis methods for the pharmaceutical and biotech sectors, is aiming to fill that gap with the development of an oral treatment composed of two non-opioid analgesics. This new formulation aims to treat the same moderate to severe pains.


Acting as a leading investor, Pierre-Marie Defrance, previous owner  of the French pharmaceutical group IPRAD, will contribute, with an 800 000 € investment on top of the obtained public funds, to finance this flagship research project, in a market estimated at $1 billion in Europe and $3 to 4 billion at the international level. 
After the co-developement agrement signed with Unither pharmaceuticals in 2017, the arrival of Mr Defrance in Aptys’s capital, highlights the relevance of the project.

Aptys Pharmaceuticals receives the WHO pre-qualification for its quality control laboratory

Specialized in the development of formulations and methods of analysis for the pharmaceutical industry and biotechnologies, Aptys Pharmaceuticals received last July the WHO pre-qualification for its quality control laboratory. 


Read more

It complements the approval already granted to the company in 2017 by the ANSM.
Aptys now figures on the list of laboratories approved by United Nations and respond to the solicitations of international humanitarian organizations and national health structures.

Solu' Nature is prize-winner of The "Sommets d’Or" competition rewards 2018

Organized within the framework of the Sommet de l’Elevage, The "Sommets d’Or" competition rewards every year the best innovations in various categories: machinery, equipment, supplies of services for the livestock breeding sector, services, digital / multimedia.

Read more

Specialized in the development and the marketing of Natural technics and solutions, alternatives to phytopesticide and antibiotic treatments, the Solu'Nature® company was rewarded in the category "supplies” for its supplemental Defi’Flor®.
This feed supplement is based on the principle of the coculture of bacteria and yeasts, inspired by the ancient tradition of Kefir grains. Administered in the first hours of life to several species of new-born animals, it helps the animal to develop its own beneficial flora.
The first-ever probiotic product to be examined by the jury of the Sommets d’Or, DEFI’Flor® is based on the results of experiments carried out notably by Vetagro’Sup (The Agricultural Vet school) and the universities of Clermont-Auvergne and Lyon.
As part of the scheme to reduce the systematic use of antibiotics, DEFI’Flor® constitute an encouraging alternative.

Biopôle Clermont-Limagne | Riom Site Chronicle of a successful conversion process

The Biopole Clermont-Limagne has three sites respectively situated to Saint-Beauzire, Riom and Clermont-Ferrand, forming a set of more than 20 000 sqm of laboratories dedicated to the welcome of life sciences activities.

Read more

The Riom site is a former site of preclinical research belonging previously to the MSD group. It has been transferred in 2013 to the SMO Biopôle Clermont-Limagne which now offers the premises for rental to biotechnology companies. 


The takeover of this site represented an ambitious project, considering the buildings size. The Riom Site is indeed endowed with a capacity of 12 000 sqm on a park of about 4 hectares, with as main asset the high level of equipment of its infrastructures : 7 000 sqm of laboratories furnished in accordance with GLP/GMP standards (analytical laboratories, production laboratories, 1200 sqm of animal housing) and 5000 sqm of offices and storage,  enables to meet real property needs of companies, whatever their size. 


SMO biopole Clermont-Limagne achieves on the Riom site a very satisfactory occupancy level today: about 70 % of premises are already invested by about ten companies and hundred employees.

Health, chemistry, environment, bio-computing … these companies offer a new life to these buildings which contitutes a development opportunity for one of the rising sectors of our territory.


Discovery of innovative treatments against persistent infections.

Fee For Services and R&D in pharmacology of pain.

Green Chemistry company that designs and develops innovative processes to rethink the life cycle of plastics.

Engineering office specialized in expertise/consulting on natural environment (habitats, fauna and flora).

Development of a technology of in vivo messenger RNA delivery to prevent and treat various diseases.

Service company specialized in: bioinformatics, IOT for laboratories, and secure e-commerce website.

High value added fine chemistry for the pharmaceutical, cosmetic, chemical and biotechnological industry.

Research and Development in cosmetic products.

Innovative nutritional solutions for preventing cardiometabolic diseases and provision of nutritional support for patients.

Agreement reached for the financing of the METEX PDO/AB production unit and creation of the METEX NØØVISTA company

METabolic EXplorer (METEX), an industrial biochemical company specialising in the development and industrial application of green and sustainable fermentation processes, announces the financing of its planned propanediol (PDO) and butyric acid (BA) production unit at the Carling Saint-Avold industrial Platform, for a total of €47.7 million.


Read more

The METEX project will receive financing from local public and private stakeholders.


METEX concurrently announces the signature of an agreement with Bpifrance for the creation of METEX NØØVISTA, a joint venture to be majority-held by METEX that will build and operate this unit.


The planned production unit will have a capacity of 24 kt/year, to be achieved in two stages: a first, 6-kt stage (5 kt of PDO and 1 kt of BA) and a second, 18-kt stage (15 kt of PDO and 3 kt of BA).


It is reminded that the total financing to be provided by the METEX NØØVISTA joint venture partners for the project, excluding buildings and utilities, will stay at the same maximum amount of €37 million as estimated in January 2018.


Bpifrance would make an equity investment alongside METEX. METEX is committed to providing €17.2 million in cash along with an exclusive licence and sub-licencing rights. METEX will have a 55% stake in the joint venture. The licencing agreement also provides for an additional valuation of the technology when the project moves into the second stage. Last, in the framework of the Voluntary Economic and Social Development Agreement signed by the Total group, the State, and the Region, local public and private stakeholders will provide financing for this project.


With the technology provided by METEX, it is possible to obtain two distinct products (PDO and BA) using a single process. These two products have several markets, the main ones being, for PDO, cosmetics and bio-based polymers, and for BA, animal nutrition and flavours and fragrances.

METabolic EXplorer: the construction of its PDO/AB production unit is anticipated to begin at the end of 2018

The project of construction of a 1,3 propanediol (PDO) and butyric acid (BA) production plant on the chemicals platform of Carling Saint-Avold in Moselle,  is progressing in compliance with the timing announced by METEX in early 2017.


Read more

METabolic EXplorer announced that it has received the certificate of submission and completeness for its environmental permit application and the certificate of submission for the construction permits applications. 

A last milestone is expected at the end of June, when the total investment required should be confirmed, as well as the aid package, estimated at around €15m from public and private stakeholders, which will be allocated to this project. 

“If everything goes to plan” says Benjamin Gonzalez, METabolic Explorer CEO, “the construction of the plant should begin during the last quarter of 2018”.

Cyclopharma announces the acquisition of its French production facilities by the Curium Group.

The development and commercialization of the most innovative molecules coming from Cyclopharma’s pipeline will continue in a new company under the current Cyclopharma France and US management team. 

Read more

Cyclopharma, an innovative pharmaceutical company specialized in molecular imaging solutions, announces the acquisition of its French production facilities by Curium. 


The worldwide development and commercialization of molecules coming from Cyclopharma’s pipeline will be pursued by a newly formed company, managed by the current Cyclopharma France and US management team.


The divestiture of Cyclopharma’s french commercial activities to Curium is now complete and will allow the Cyclopharma management to focus on the new company’s mission of developing and commercializing best-in-class molecular imaging and therapy drugs. With this new organization, Cyclopharma is committed to provide patients and customers access to innovative diagnostic and therapeutic solutions.


Cyclopharma’s R&D programs, Cyclopharma US, and international development projects will be transferred to a new company owned by Denos, Cyclopharma’s historical shareholder. The new company will pursue the development of compounds from Cyclopharma’s pipeline in order to ensure their access to the market and their commercialization in France, the United States, and the rest of the world. The new company will continue to expand its presence in the United-States and in other parts of the world.

"All the aspects of sterilization”: ICARE organizes a day on the sterilization of medical devices

Service supplier laboratory dedicated to the microbiology, Icare Laboratories organize on May 31st near Clermont-Ferrand, a day of conferences dedicated to the sterilization of medical devices.

Read more

Entitled "All the aspects of sterilization", this day will take place from 9:00 am to 5:00 pm in the Studio 120 in Cournon d’Auvergne, Puy-de-Dôme, near the Icare Laboratories.
The program includes 8 conferences dealing with methods of bioburden determination, sterility monitoring methods, moist heat sterilization processes, sterilization techniques-ethylene oxide (EtO), gamma radiation, and the maintenance of the sterile barrier. 
Two industrialists will testify of their experiments in the fields of aseptic filling and the development of analytical methods for the sterilization of a complex device (validation and control).

Detailed program (in french):
Registration :
Please note that there are a limited number of places.

CARBIOS achieves a major milestone in the optimization of its biorecycling process of PET based plastics

CARBIOS, pioneer company in the field of bioplasturgy, announces a major milestone in the optimization of its biorecycling process of post-consumer PET plastic bottles, making it possible to strengthen its economic competitiveness and accelerate its scaling up towards the industrial demonstration stage. 

Read more

Previously, CARBIOS announced that it had discovered a particularly well-suited enzyme to degrade PET plastics into their original monomers: PTA (terephthalic acid) and MEG (mono ethylene glycol). 
Following these results, work has been undertaken to optimize the enzyme used in CARBIOS’ biorecycling process, with the support of the teams from Toulouse White Biotechnology (TWB), and in particular the Engineering Laboratory of Biological Systems and Processes (LISBP). A molecular modelling study has been carried out to analyze the relations between the 3D structure of the enzyme and its efficiency. This has made it possible to set targets enabling to improve performance and achieve a conversion rate that only CARBIOS can claim today. Thus, the time of hydrolysis has been divided by three, 97% conversion being obtained after 24 hours of reaction. Such a result enables to optimize the profitability of the process and significantly increase the flows of PET waste that can be treated enzymatically.

Towards an acceleration of the industrialization stage

Given its progress, the company decided to accelerate these developments and initiate the industrial demonstration stage in 2019 with the set-up of a 10,000 metric tons plant that will produce the first volumes of virgin PET from our technology by mid-2021.

Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group.

Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging. 

Read more

Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, neurologic and cardiac imaging drugs to healthcare professionals. Acquired by Denos in 2013, Cyclopharma employs more than a hundred employees, at its 7 production and R&D sites in France. Today, Cyclopharma is a leader in molecular imaging, a technique which improves patients’ quality of life, efficacy of treatment while reducing costs. 

Curium was created in January 2017 by uniting IBA Molecular and Mallindkrodt Nuclear Medicine LLC and has made a stock purchase offer to acquire Cyclopharma from Denos. With this proposed acquisition, Curium intends to increase its production capabilities to provide their customers optimal access to the tracers, meeting growing product demand. Curium would integrate the acquired production facilities into their existing radiopharmaceutical manufacturing network. This enhanced network would enable the commercial production of new compounds, as well as support the development of new products. 

Upon the completion of the offer, R&D and international activities of Cyclopharma would be transferred to a dedicated subsidiary which would be owned and managed by Denos. The subsidiary would take over Cyclopharma’s current R&D projects, and commercialize those molecules in France and worldwide directly or with industrial partners. 

The divestiture of the manufacturing assets and French commercial activities will allow the management and development team to focus on the new company’s mission of developing and commercializing best-in-class molecular imaging and therapy drugs. The new entity would be based in both France and the United-States. The international presence will build a strong platform for developing and commercializing products. 

The first goal of the new company will be to launch EstroTep®, a new radiopharmaceutical tracer bringing an innovative approach for breast cancer diagnosis in Europe, and seek FDA clearance in the US. EstroTep® is considered by the scientific and medical community as a useful tool in the management of breast cancer.

OAAS congratulated by the Trophies of the innovation of the GCE 63

On January 19th of this year, OAAS received the " Trophée de l’Innovation” during the celebration of the 40 years of the GCE, in the presence of Olivier Bianchi, mayor of Clermont-Ferrand and president of Clermont Auvergne Métropole and Claude Barbin, president of the CCI of Puy-de-Dôme.

Read more

Specialized in bioinformatics, OAAS is focused on data integration taken from different domains, thanks to the algorithms of bioinformatics, but also on IOT for laboratories, and secure e-commerce website.

With a solid network of specialized partners in related fields of patents, electronics, artificial intelligence and Bioinformatics Platform , OAAS is mainly targeting small and medium-sized companies that do not have integrated solutions for the management of their data, and wishing to improve their business efficiencies: data collection, data mining and e-commerce.

he annual Trophies of the GCE (Grouping of the Entrepreneurs of Puy-de-Dôme) highlights the success and the know-how of creators, project leaders or business buyers while valuing the sense of initiative.

These Trophies are organized by the GCE, in partnership with the CCI Entreprendre en France, supported by a network of economic partners (CCI Puy-de-Dôme, ERDF Services Clermont-Ferrand, AG2R La Mondiale, RSI Auvergne, CFDP, Banque Populaire du Massif Central, Société Générale, Ordre des Experts Comptables, Crédit Agricole).

CARBIOS announces the development of a new process enabling to depolymerize PET polyester fibers from textile waste

CARBIOS announced that it has taken a new step forward in the development of its enzymatic depolymerization process rending it applicable to PET polyester fibers from textile waste.

Read more

After the successful demonstration that enzymatic depolymerization applied to PET plastics enables the virtuous cycle of a return to a virgin PET, CARBIOS opens a new major market by depolymerizing 100% PET textile waste fibers into their original monomers: PTA (terephthalic acid) and MEG (mono ethylene glycol). 


Indeed, polyester is today the single-largest-volume fiber produced globally, taking about a 50% share of the overall fiber market . The dominant type of polyester is polyethylene terephthalate most commonly known as PET. Each year, 43 million tons of PET are produced for the fiber market , compared to 15 million tons dedicated to the production of plastic bottles. 


The key objective of this new process developed with CARBIOS academic partners (INRA/TWB/LISBP) and supported by ADEME Auvergne Rhône-Alpes, is to provide: 
- the recycling industry, a competitive solution to upcycle post-consumer PET polyester fabrics; 
- and the textile industry, the ability to use recycled PET fibers that can fully replace those made from fossil resources. 


Thus, contributing to several environmental benefits as the reduction of waste to landfills and reduction of carbon footprint.

OBJECT AS A SERVICE (OAAS) joined the Biopôle Clermont-Limagne.

OAAS, created in march 2016, is specialized in bioinformatics.

Its small multidisciplinary team is focused on data integration taken from different domains, thanks to the algorithms of bioinformatics, but also on IOT for laboratories, and secure e-commerce website.

Read more

OAAS is mainly targeting small and medium-sized companies that do not have integrated solutions for the management of their data, and wishing to improve their business efficiencies.
It provides them with services tailored to their needs: OAAS-Grab, for data collection, OAAS-Explore, for data mining and OAAS-Sell&Connect, for the sale (e-commerce and marketplace site ).

Accompanied by the region for its creation, OAAS is also supported on an R&D project in senior IOT by a Bourse French Tech.

CARBIOS successfully completes final key stage of the THANAPLAST™ project and receives €1 million from Bpifrance.

Carbios announced the successful completion of the fifth and final key stage of the THANAPLAST™ project and the payment of €1,021,871 from Bpifrance for having achieved this new milestone.

Read more

The THANAPLAST™ project accounts for a budget of €22 million over 5 years, including €15 million directly raised by CARBIOS. Financing support from Bpifrance represents €9 million, of which €6.8 million were directly allocated to CARBIOS in successive installments at the completion of the five key stages of the project.


As lead of this program, CARBIOS has brought together key academic and industrial partners within THANAPLAST™ (INRA, TWB, INSA de Toulouse - LISBP/Critt-Bioindustries -, CNRS, Université de Poitiers, Limagrain Céréales Ingrédients, Group Barbier and Deinove). Right from the beginning in 2012, 60 scientists have been involved to ensure the development of CARBIOS’ bioprocesses. Carried out over 5 years, this collaborative project has just been successfully completed in accordance with the initial timing and objectives.


During the final key stage, CARBIOS published several announcements on successful developments of its technologies. In the field of biorecycling, CARBIOS demonstrated its ability to synthetize PET oligomers made out of terephthalic acid coming from its biorecycling process of PET plastic bottles, and then to produce virgin PET from post-consumer PET plastic bottles treated by enzymatic hydrolysis. Beyond these results comforting the technological value of the innovations developed with the THANAPLAST™ project partners, CARBIOS pursued the industrialization of its biodegradation process through the joint-venture CARBIOLICE, created in 2016 with Limagrain Céréales Ingrédients and the SPI funds run by Bpifrance.


This 5-year research and development program has led to the emergence of two valorization routes for plastics end-of-life: the biodegradation of PLA-based plastics and the recycling of PET, the predominant plastic in our bottles and trays. Highly specific enzymes have been discovered and optimized to enable their introduction at a very high temperature within a plastic and to improve their catalytic properties. This work has led to the development of very innovative processes whose industrial implementation is already conducted within CARBIOLICE since 2016. 


The next step will be to launch a PET biorecycling pilot plant. 

Solunatures: natural technics and solutions, alternatives to phytopesticide and antibiotic treatments.

Specialized in the development and the marketing of alternative solutions to phytopesticide and antibiotic treatments, the company Solu’Nature joined the Biopôle Clermont-Limagne this fall 2017.

Read more

The innovative solutions proposed by Solu’Nature are particularly relevant for the arboricultural sector and gardening, beekeeping, or even animal health. The company is working on alternative solutions to conventional treatments that allow a rational use of phytopesticide treatments, fertilizers, or antibiotics. 

Solu' Nature so proposes a range of probiotics intended for the poultry and the rabbits and for the young ruminants, the piglets and the foals, allowing to decrease drastically the use of antibiotics.

The company also works on hygiene in livestock building, nourishing and protection of bees and plant protection and fertilization.

For all these specialities, Solu' Nature addresses both the professionals and the general public.

StrainChem is established on le Biopôle-Clermont-Limagne

StrainChem is specialized in sustainable organic and medicinal chemistry, adapted to environmental standards. It has recently been established on the Biopôle Clermont-Limagne.

Read more

This company is one of the winners of the New Deal Biotech competition organized in 2015 by the Biopôle Clermont-Limagne, in partnership with the Regional Development Agency, the Busi incubator and Auvergne biosites.

Its creator, Jean-Jacques Youte has been supported in this context by the teams of the incubator and the Biopôle Clermont-Limagne. He has benefited from the best conditions and has developed his project during 18 months, served by a welcome and integration program (income and housing) allowing him to be totally committed to the project.

StrainChem maintains an ever expanding inventory including molecular structures not currently available in the market.
From this database, the company proposes to industrials to produce tailor-made innovative compounds like reference compounds, metabolites, impurities, building blocks, new scaffolds. 
New molecules and improved existing molecules (efficiency, availability), concerns pharmaceutical, cosmetic, agro food and chemical industries.


StrainChem has also developed an innovative process for peptide synthesis which is proposed in the form of License to the industrialists.

This process presents numerous advantages compared with the conventional processes. Fast, (tripeptides realized in 3 steps instead of 6 steps until then necessary), economic, ecological and effective, it is also reproducible on a large-scale.

Cyclopharma: Saint-Beauzire’s cyclotron is back in service

The cyclotron of Clermont-Ferrand, that has been dormant since two years, is back to service today. In 2015, the DENOS group acquired the Cyclopharma company and then decided that the Saint-Beauzire site was too old to be kept in operation. However, the head office of the group was maintained on the Biopôle Clermont-Limagne.

Read more

Thanks to a 500.000-€ investment, Cyclopharma relaunches now its cyclotron that will alleviate  the 6 other production sites of the group. It will produce the FDG molecule (fluorodesoxyglucose), a radio tracer used with a PET Scan for the visualization of tumors.

The site of Saint-Beauzire ideally located in the center of France, allows a fast delivery of the customers, a main advantage for products with a life span of no more than 10 hours.

The return to service of the Cyclotron will also allow the 6 other sites to concentrate on the production of two new molecules, intended for the diagnosis of prostate cancers and breast.
Thanks to the last one, dedicated to the breast cancer, Cyclopharma is developing in the United States. The company intends moreover to invest a million euros in the American soil with as a bonus the installation of one to three sites before five years. 

Carbios products virgin PET from post-consumer plastic bottles treated by enzymatic hydrolysis

Carbios, pioneer company in the field of bioplasturgy, today announces that it has taken a new step forward with the production of virgin PET made out of terephthalic acid coming from its biorecycling process of post-consumer PET plastic bottles.

Read more

CARBIOS previously demonstrated that it had successfully synthetized PET oligomers made out of terephthalic acid coming from its biorecycling process of PET plastic bottles. This was the first step towards the production of PET.

The following step consisting in the synthesis of virgin PET made out of these oligomers has now been completed confirming by then the potential of CARBIOS’ technology for the recycling of plastic bottles waste into virgin PET polymers.

The next short-term goal is now to demonstrate that this virgin PET is suitable for the production of new bottles, thus paving the way to circular economy for PET plastic products, opening promising prospects for the treatment of a wide range of this type of waste.


IPC joins the Biopôle Clermont-Limagne

The Industrial Technical Center 3S’inPACK joined in september IPC, the Industrial Technical Center dedicated to innovation in plastics and composite materials. Until now based in Aubière (63), the team that was working under the auspices of 3S’inPack now constitutes the 5th IPC unit in France and settles on the Saint-Beauzire site on the Biopôle Clermont-Limagne.

Read more

IPC supports companies, in particular SMEs and micro businesses, solving their problems linked to plastic and composite materials. The center is interfering in R&D, innovation, technological and competences transfer.
It draws on the France's Plastic Processing Federation and its unions, and develops partnerships with technical and scientific actors: competitiveness clusters and technical centers, universities and engineering schools.


IPC employs nearly  125 people in France, located in Chambéry, Laval, Oyonnax, Alençon and now Clermont-Ferrand, whose site enhance its expertise, with packaging as a key point.


The 3S’inPACK competence around the "packaging + product" duo will be carried out again in IPC: Food and Environmental Safety, stability of packaged products, functional and sensorial quality. The team’s interventions rely on an expertise gained over the last 20 years in the fields of food packaging: analyses, tests, diagnostics, expertise, technological watch, innovation and design and eco-design. Digital technologies enable it to make predictions linked to the "packaging + product" duo, calculations and modeling to realize risk analysis and to develop eco-design.

METabolic Explorer announces its project for the construction of a PDO/BA production plant in Moselle (France)

METabolic EXplorer (METEX), an industrial biochemical company specialising in the development and industrial application of green and sustainable biochemical processes, announced on 3 july the signing of an agreement with TOTAL Développement Régional (TDR) for the construction of a PDO/BA (1,3 propanediol and butyric acid) production plant. 

Read more

The Carling Saint-Avold chemicals platform in Moselle (Greater East Region) has been chosen as the site for this facility. METEX considers the construction of this plant a top priority for the implementation of its new strategy, presented last May. 

A METEX-owned production unit to retain the majority of the value generated by this technology

METEX’s goal is to become the leading supplier of butyric acid for animal nutrition and the top-ranked producer of non-GMO 1,3 propanediol (PDO) for use in cosmetics. To achieve this goal and retain the majority of the value generated, METEX has decided to prioritise the construction of its own production facility. 

The objective is to construct a production plant with a capacity of 24 kt in two stages: 

  • A first, 6-kt stage (5 kt of PDO and 1 kt of butyric acid) 
  • A second, 18-kt stage (15 kt of PDO and 3 kt of butyric acid) 

METEX has assessed several sites that could host this PDO/BA plant, including the Carling Saint-Avold site. A Voluntary Economic and Social Development Agreement was signed in 2014 by the State, the Region, and TOTAL Petrochemicals France to spur further development of the Carling Saint-Avold platform. 

Following an initial assessment phase of the METEX project by TOTAL, METEX agrees to carry out studies for the construction of its PDO/BA plant at the Carling Saint-Avold site. TOTAL agrees to make every effort to mobilise all stakeholders and to assist METEX in obtaining public funding. 

Last, as the first stage of the industrial project will create 43 jobs in the Moselle, on 29 June 2017, the municipal districts of the Communauté de Communes Agglo Saint-Avold Centre Mosellan approved the grant of a €200,000 subsidy to METEX.

Everything is now in place to launch the studies phase for the construction of this production facility, with this phase being financed mainly by METEX’s partners. 
TechnipFMC has been chosen to carry out the preliminary engineering studies to validate the technical and economic conditions for the construction of the plant on the Carling site. 

Based on the conclusions of these studies, and once METEX and its financial partners have determined the means of financing the investments for the first stage (estimated at €25 million), the final decision on the investment is expected by late 2017/early 2018. If it is decided to move forward with the project, construction is expected to begin late in the first half of 2018 (with a leeway of 3 months), in line with the announced calendar. 

Successful 70 000 liters scale-up validation of AFYREN’s semi-industrial fermentation

AFYREN, the specialized company into carboxylic acids using the fermenting process, announced the successful results of the industrial scale-up of its AFYNERIE technology. The Company, based at the Biopôle of Clermont-Limagne, Saint-Beauzire (France), realized a major industrial proof-of-concept through the validation of its fermenting technology with 70 000 liters.

Read more

The erected platform, located at Cristal Union’s site in Clermont-Ferrand, led to the production of “hundreds of kilograms » of bio-based organic acids from « tons of sugar-based by-products. These acetic, propionic, butyric, isobutyric, valeric, isovaleric and caproic acids are dedicated to the nutrition, chemicals, and cosmetic sectors”.

«Based on this scale-up AFYREN is joining the exclusive ranks of Biotech Start-ups ready for industrialization of production. This success helps us working with confidence on our fund raising objective», welcomes Nicolas Sordet, AFYREN’s CEO, adding that « clearly we are raising 10 millions of euros to finance our growth, our scale up from industrial pilot to production scale, and indeed to represent us as one of the most advanced companies in the world when it comes to bio-based products substitutable to petro-sourced molecules».

This further step on the road to full-scale production is now being taken and it will allow the company to reinforce its expectations for the construction of an industrial unit. « Currently we are involved on the industrial deployment of the process into an existing fully integrated sugar industrial platform, with high potential of technical and services-based synergies. The objective being to construct the first industrial unit in France », emphasizes Jérémy Pessiot, AFYREN’s Founder & Managing Director.

Carbios: new success with the synthesis of PET oligomers from biorecycled terephthalic acid

Carbios, pio-neer company in the field of bioplasturgy, has taken a new step forward with the production of PET oligomers made out of terephthalic acid coming from its biorecycling process of PET plastic bottles.

Read more

The synthesis of PET is carried out in two major steps:

  • The first, considered to be the most critical, consists in the synthesis of PET oligomers from monomers of terephthalic acid and mono ethylene glycol.
  • The second allows the synthesis of PET by polycondensation of the oligomers previously ob-tained.

By succeeding in this first step, CARBIOS demonstrates that it is now possible to use PET plastic waste rather than fossil resources for the synthesis of PET oligomers.

Carbios previously demonstrated that it had successfully depolymerized PET bottles into its initial monomers. A first scale up of the process has since been performed. After a proof of concept at the scale of one hundred milliliters, this depolymerization was carried out in reactors of 5 and 100 liters. At such last scale, 20 kilos of PET have been treated and depolymerized at 90%. Performances of the depolymerization process were perfectly identical regardless of the reactors volume, showing by then the strength of this technology. At the end of the depolymerization process, the terephthalic acid produced has been collected and purified. Its purity reaches a level above 99% and analytic technics of reference do not allow to make any difference with commercial terephthalic acid pro-duced from oil.

METabolic EXplorer presents its new development project and discloses its new ambitions.

The METabolic Explorer technological process, oil-free, pollution-free production of consumer products (textiles, plastics, animal feed, etc.) having similar or higher performance, with better competitive cost conditions. 

Read more

This breakthrough solution whereby the same process can be used for making two different products (butyric acid and PDO). It addresses various markets, the two main ones being animal feed, with butyric acid, and cosmetics, with PDO. 


METabolic EXplorer has presented its ambitions: become the market leader for natural butyric acid (BA) for animal feed and become the benchmark producer of GMO-free PDO (1,3 propanediol) for cosmetics applications. 


To fulfil these ambitions, METEX plans to build a PDO/AB production facility. 
The direct industrial production of its products will allow METabolic Explorer to keep the whole of the value generated by its technology.


METEX wishes to build a production facility having a 24 kt capacity, in two stages: an initial 6 kt section (5 kt of PDO and 1 kt of butyric acid), and a second 18 kt phase (15 kt of PDO and 3 kt of butyric acid).

Construction work should start toward the end of the first half of 2018 (with a latitude of around three months). By this time the company will have selected the prime contractor, project management assistance and financial partners for the project. 


METEX is targeting an eventual 20% share of the market for naturel butyric acid in animal feed, a 50% share of the market for PDO in cosmetics, and a 40% share of the market for PDO in the PTT textile market. 


More information on the média room

Crexeco joins the Biopôle Clermont-Limagne

Crexeco is an engineering office specialised in expertise and consulting on natural environment (habitats, fauna and flora). Between research and ecological engineering, it offers independant expertise based on both scientifical and naturalist approach of ecology.

Read more

The Crexeco expertise concerns natural environments and, take the form of various fields like regulatory studies, applied research and teaching.

From preliminary studies to ecological monitoring of infrastructures and wildlife inventories, Crexeco supports any project leader in successive steps of the project.

It also develop applied research studies allowing to answer to crucial questions posed to project leaders and public authorities.

Finally Crexeco promotes the diffusion of knowledge by teaching on ecology and wildife conservation, and reading specialized litterature. 

Crexeco has established its offices on the Biopôle Clermont-Limagne (Riom site) in April 2017.

IXO Private Equity invests 2,7M€ in Cyclopharma

Created in 2000 on the Biopole Clermont-Limagne, Cyclopharma is the French leader specialized in the development and the marketing of solutions of molecular imaging for the management of the patient both in oncology and in neurology. 

Read more

The capital increase will so allow to finance the research for new molecules biomarkers and the development of its international activity, in particular in the United States and in Europe.

Based on the site of Saint-Beauzire, Cyclopharma realizes more than 20 M€ of turnover and employs 119 collaborators distributed on the seat and 7 production sites, the meshing of the territory of which is adapted to the constraints of this short half-life drugs. 


Cyclopharma develops, produces and markets radiotracers who are used to realize positron emission tomography (PET) medical imaging.   The use of this radiopharmaceutical medicine coupled with the PET technology meets the healthcare professionals' and patients' needs by allowing a diagnosis of the whole body and a coverage more adapted to their pathology.

Since 2013, Cyclopharma is mainly detained by Denos Pharma, who participates in the operation. The capital increase of a total amount of 5,4 M€ is thus signed by iXO Private Equity at the level of 2,7 M€, Denos Pharma at the level of 1,9 M€, Sofimac at the level of 0,6 M€, and other already present shareholders for the balance.


The team organized at that time, taken by the Managing director Bernard Landes, emphasized the Research and development by rationalizing the projects and by increasing significantly the R&D budget. It increased twofold since 2014 and represents from now on more than 10 % of the turnover. Today, these efforts pay off, and two new molecules, used for the diagnosis of the breast and the prostate cancers, have been granted marketing authorization in France and are about to be in phase of commercial launch.


In parallel, Cyclopharma moves forward on development projects which will allow the company to complete its offer (2 molecules at the clinical testing stage) and its geographic coverage, in Europe and in the United States.

Creation : BioFilm Pharma prepares the next generation of antimicrobials

Since 2005, BioFilm Control is specialized in the detection of biofilms, cellular communities welcoming the development of antibiotic-resistant bacteria, responsible for infections which can be mortal. It is estimated that up to 10 million deaths will be caused by these infection in 2050.

Read more

While the first diagnostic test from Biofilm Control will be available on the market in 2018, the company has created in april 2017, BioFilm Pharma, specialized in the treatment of these biofilms.
BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment of “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for Health Care system in high-income countries (4 billions €).

BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy.

The company has already 5 compounds in its pipeline and is 3 years up to proof-of-concept in patients for potential blockbusters. It has already 2,4 M€ secured by a syndicate of historic investors or grants and it is looking for 20 M€ funds to engage CMC, preclinical and clinical studies.


CARBIOLICE, prize-winner of the Cleantech prize for the "Better Partnership innovative SME / Major Corporation".

Carbios, an innovative green chemistry company specializing in enzymatic bioprocesses applied to plastic and textile polymers, received on March 9th, the Cleantech prize for the "Better Partnership innovative SME / major corporation", awarded by the AFIC (French private equity investors association) and EY.

Read more

This distinction rewards the partnership between CARBIOS, Limagrain Céréales Ingrédients and the SPI Fund “industrial project companies” operated by Bpifrance, an alliance which became a reality by the creation of the joint-venture CARBIOLICE in September, 2016.

This company resumed the production and marketing of bio sourced and biodegradable plastic granules of Limagrain Céréales Ingrédients (known under the brand Biolists ®) and will integrate the technological innovations dismissed by CARBIOS. Through its production unit of a 4 000 ton capacity a year, CARBIOLICE commits the industrial and commercial development of the CARBIOS technology (enzymatic biodegradation of plastics).

This innovation is intended for the market of flexible films (mulching, bags and sacks, industrial films, routing films, food packaging) and for stiff applications (farming and horticultural sector, disposable dishware). It will answer in a more competitive way to the new stakes of the law for Energy Transition and Green Growth.

NEURONAX obtains the authorization to start its phase i clinical trial in france and belgium and strengthens its patent portfolio

NEURONAX, the biopharmaceutical company specialized in neuronal regeneration, has been authorized to start its Phase I clinical trial by the Healthcare Authorities (French National Agency for Medicines and Health Products Safety (ANSM) for France and The Federal Agency for Medicines and Health Products (FAMHP) for Belgium).

Read more

This first clinical trial in humans with the NX210 product is titled ” A Phase I Study to Investigate the Safety and Potential Activity of Single Intrathecal Administration of NX210 in Patients with Spinal Cord Injury “. The primary endpoint of this study is to evaluate the safety of NX210 in patients with acute spinal cord injury. Secondary and exploratory endpoints include biological effectiveness of the experimental drug and functional recovery.

The dose escalation study, will take place in at least 5 French and Belgian hospitals and will recruit up to 36 patients. The coordinating investigators are: Prof. Chazal and Dr. Sakka of the CHU of Clermont-Ferrand for France, and Prof. Raftopoulos of the Université Catholique de Louvain (UCL) for Belgium.

Research on embryogenesis has made it possible to discover a protein called SCO-spondin. This protein is very involved in the formation of the central nervous system. In humans, the organ producing SCO-spondin disappears after birth thus strongly reducing the chances of “regrowth” of neurites. The NEURONAX research team extracted and synthesized the peptide of interest (NX210) from SCO-Spondin and then characterized its different properties. With a unique mechanism of action, NX210 has demonstrated neuroprotective and neurodegenerative properties suggesting applications in the treatment of pathologies of the nervous system, especially in cases of spinal cord injury but also with a high potential in neurodegenerative diseases.

Preclinical studies have demonstrated the good safety profile of the product as well as its efficacy on the protection of nerve cells, the regrowth of neurites and especially the recovery of functionality, including motricity in the injured animal.

NX210 has been granted the status of “Orphan Drug Designation” by the European Medicines Agency (EMA). Several patents, some of which have been recently filed by NEURONAX, provide an enhanced protection to the product and cover in particular: manufacturing of the peptide, its application in neurodegenerative diseases, its use in combination with stem cells and its anti-apoptotic activity for the neurons.

Galilait is setting up in the Biopôle on the Clermont-Ferrand site

Since January 2015, the Biopôle Clermont-Limagne welcomes Galilait, a laboratory specialized in the realization of analyses and the provision of services in the field of food safety in the milk sector.

Read more

The core business of Galilait is to analyse milk samples coming from near 8 000 farms.  In this way, with each producer, at least three times per month, the laboratory makes compositional analyses (fat matter, proteins…) and quality analyses (plate count, somatic cell count, and search for antibiotics…). These parameters are essential data to establish the milk payment for each producer.

Galilait also realizes analyses for the control of performance by monitoring each animal in order to obtain a genetic improvement of herds, and to plan their health monitoring and their food program. This activity is now based on the Biopôle.
By also conducting microbiological and nutritional analyses on all products of the dairy industry, Galilait is a major actor in food safety for the final consumer.

Galilait is a non profit association product of the merger in 2008 of Alizé laboratories in Rhône-Alpes and Cilal in the Puy-de-Dôme. 

On the Biopôle Clermont-Limagne, in Clermont-Ferrand, the laboratory now occupies near 250 m2 divided into cold storages and laboratories, new facilities useful for its development and its modernization. In this context, Galilait has installed two new equipment’s for the quick identification of bacteria, moulds and yeasts and susceptibility testing.


Bio-entrepreneurs, on the way to Auvergne

Auvergne and the Biopole Clermont-Limagne launch a new European competition dedicated to project leaders in the fields of life sciences: New DEAL Biotech. We are offering a 12-month salary, use of a laboratory, paid rental accommodation as well as bespoke support to 10 project leaders eager to set up business in Auvergne.


Read more

Exceptional conditions for bio-entrepreneurs in a metropolis boasting benchmark status in biotechnology ! This operation is organized by the Biopôle Clermont-Limagne and the Agence des Territoires d’Auvergne (Regional Development Agency for the Auvergne Territories), with the Conseil Régional d’Auvergne (Regional Council), the BUSI incubator, the Naturopôle of Saint-Bonnet de Rochefort and the Bioparc of Vichy.

Registration and further information : You have until 22 september 2015 #NewDealAuvergne

Alphanosos will join the Biopôle on may

Alphanosos is a young company focused on the discovery of new therapeutic molecules to combat bacterial persistent infections. Its aim is to identify innovative treatments able to find and dismantle biofilms often resistant to antibiotics.

Read more

Alphanosos has a first patented treatment in oral health. The company begins in dermatology and veterinary to develop compounds which can be given up at the stage of validation to the animal.

Beyond this first horizon, the activities of Alphanosos can concern numerous pathologies involving biofilms as caries and gingivitis, eczema, acne, rhino sinusitis and chronic lung obstructions, but also the development of new antibiotics.

With its perspectives, the company expects to obtain via some future fund raising, the investments necessary for its growth.

Next May, its installation in its new laboratories within the site of Riom on the Biopole Clermont-Limagne, will be a major step in its development.

BioSilicium has been created on the Biopôle Clermont-Limagne

Created in February 2015, BioSilicium is a software publisher focusing on expert systems, traceability and quality softwares. It provides companies a tailored and optimized solution to their needs.
Its expertise covers two domains: forensic genetics and health.

Read more

BioSilicium is publishing an Expert System and a LIMS dedicated to forensic genetics. Its added value is positioned on the performance, integration into the business flow and experience in the field.
In the health sector, BioSilicium focuses on health and safety with its software bs-BioPic that ensures traceability and assessment of employee exposure to chemical & biological agents. 
The use of our innovative input methods and the usability of the system ensure traceability and performance while reducing the costs of regulatory obligations.

BioSilicium’s ambition is to focus on its expertise and become first rank international player in the fields of forensic genetics and health. Various partnerships and R&D programs enable the company to maintain its level of expertise and provide innovative solutions to its customers.

CALNESIS, experimental thermodynamics applied to industrial issues.

Created  and based on the Biopole Clermont-Limagne since the beginning of April, CALNESIS proposes to the industrialists a wide range of services in the field of the experimental thermodynamics, with a specialty it calorimetry. 

Read more

Services of measure, study, development and training, Calnesis supplies to its customers its expertise as for the measure of the physical-chemical variables necessary for their industrial applications. 
The skills of the company concern particularly the development of techniques or innovative protocols answering specific problems: corrosive or toxic character of the studied, high-temperatures and pressures, viscous fluids, etc.
CALNESIS relie on its partnership with the Institute of Chemistry of Clermont-Ferrand from which arise its two founders, Mickaël SIMOND and Jean-Claude NEYT, both doctors in Physical Chemistry.
The company collaborates in a privileged way with the various research teams of the institute and benefits from its expertise in the implementation of innovative approaches from calorimetry. It is so able to propose its customers increasingly innovative solutions.


Icare SAS strengthens its positions in Brazil by Medlab Produtos Diagnósticos Ltda's repurchase

In March 2015, the ICARE SAS company, French leader in the control of contamination of health products, acquired 100 % of the partnership shares of the Brazilian company Medlab Produtos Diagnósticos Ltda situated to São Paulo.


Read more

The operation was realized through its Brazilian subsidiary, the ICARE company doh Brasil Participações Ltda. 
With this acquisition, Icare strengthens its international positioning as partner of the manufacturers of medicine and medical devices. The Medlab Produtos Diagnósticos Ltda company estimates the conformity and the safety of health products by the search for contaminants, the validation of manufacturing processes and the qualification of equipment. 
The Medlab Produtos Diagnósticos Ltda company possesses an expertise for more than 20 years in the evaluation of the biocompatibility and the toxicity of medical devices, medicine, cosmetics, agrochemical products and disinfection products.

Carbios receives in its new premises the President of the Regional Council of Auvergne and elected officials

On February 16th, Carbios was visited by René SOUCHON, Chairman of the Regional Council of Auvergne and elected representatives to inaugurate its new setting-up.

Read more

Carbios indeed moved on the Biopole Clermont-Limagne into a building where the company was able to set up its offices and its new pre-industrial development laboratory. This moving in allows Carbios to develop its processes up to the pre-experimental scale. The installations contain a microbiology and enzymology platform, an analytical platform, a fermentation processes platform, and a plastic processing platform which will be put into service during summer.
Historical support of Carbios, the Region helped the company at the level of 549.000 €, via the FIAD (Auvergne Sustainable development Investment fund). This help allowed Carbios to be structured by recruiting 10 "very qualified" jobs in particular 3 doctors in biology and 4 research engineers for R&D missions. The Region and Carbios often finds themselves through the Smart Specialisation Strategy, the industrial mutation of the territory and the support for the emergent technologies.


Prevention of the occupational deafness: Echodia and the INRS receive one Decibel d’argent for Echoscan

Echodia and the INRS* have just been rewarded by a Decibel d’argenr for EchoScan, a device intended to prevent the risk of hearing deficit by measuring the peripheral hearing fatigue. 

Read more

Developed by the INRS and made by ECHODIA, the device aims especially the occupational medicine.
The exposure of the employees to high noises or ototoxic substances can hearing impediments. 
Echoscan aims at preventing these risks. Thanks to fast, non-invasive and objective measures, it tests the functioning of the internal and average ear as well as the hearing nerve centers.

Echoscan is a small ultra-light, easily transportable case which registers the acoustic oto-emissions (AOE) in an ear, while activating the hearing reflex in the other ear. The variations of amplitudes of the AOE allow to determine the threshold from which the hearing reflex is engaged. Very sensitive to the hearing fatigue, this threshold allows to identify the forerunners, before the deafness settles down.

EchoScan thus improves the early screening of the effects of the noise before even the appearance of permanent hearing deficits.


*INRS: National Institute for Research and Safety

*Created in 1991 by the National Council of the Noise, the Decibels d’Or reward French and European industrialists, elected representatives, teachers, designers, representatives of associations, researchers, showing significant, innovative or remarkable realizations regarding improvement of the sound environment.

METabolic EXplorer receives a “green light” from the US FDA* towards marketing the L-Methionine

METabolic Explorer has received confirmation of the positive result of the US Food and Drug Administration’s review of its L-Methionine notification file.

Read more

The letter of no-questions issued by the FDA leads to the addition of the first 100% bio-based L-Methionine for animal feed on the FDA inventory of GRAS (“Generally Recognized As Safe”) products and thus opens the way to its future market launch on the US market.

L-Methionine is the natural form of an amino-acid essential to animal nutrition, which means that it must necessarily be absorbed through feed additives. It is a vital feed supplement for the growth of poultry and piglets. Its market is growing fast – at a projected 5% to 6% a year between now and
2020 – and is now worth some USD 3.5 billion. 

Today’s main producers manufacture only the DLMethionine form through petrochemical processes, a form containing 50% of the natural LMethionine form and 50% of the non-natural D-Methionine form, this last being more difficult to assimilate by animals in their growth stage.
METabolic EXplorer has developed a biotechnological process for producing, via a single-step industrial fermentation, the only form of natural methionine that can be directly assimilated by animals. Compared with the numerous phases in the petrochemical process, this patented process can be adapted to already-existing fermentation capacities. 
The FDA’s positive review is an important step in the industrial development and marketing strategy of L-Methionine in markets with the highest demand.


BioFilm Control is rolling out clinical research protocols to validate its flagship product, the Antibiofilmogramme ® innovating diagnostic test

Intended to prescribe better antibiotics, the Antibiofilmogramme ® takes into account at the same time classic resistances and those linked to the capacity of bacteria to form biofilms. ( 

Read more

The behavior of biofilms is scientifically correlated to the development of resistances and hospital infections. As it also allows to return a faster result, Antibiofilmogramme® responds to expectations of clinicians and will so allow to reduce the therapeutic failures and the costs of health.
These clinical research protocols aim wound infections, in particularly diabetic feet and joint infections. Other protocols will follow for chronic infections, especially for urinary infections. The first CE markings of In Vitro Diagnostic Medical Devices are planned for 2017.
The versions for R&D use or RUO (Research Use Only) of these first Antibiofilmogramme® tests are commercialized since January 2015. 
In December, 2014, Biofilm Control concluded a new fund raising of 550 K€ with its financial partners (SOFIMAC, Entrepreneur Venture and Mipi) to finance their launch on the market.
BioFilm Control also participates in the FUI PHOSa project whose purpose is to identify bacteriophage coktails in order to struggle against joint infections, with the capacity to destroy Staphylococcus aureus and epidermidis biofilms.

METabolic EXplorer and SK CHEMICALS Co. Ltd. : signature of an exclusive agreement to manufacture and sell PDO

METabolic EXplorer and SK CHEMICALS jointly announce that they have signed a worldwide Exclusive License Agreement to manufacture and market bio-PDO (1,3-propanediol) based on METabolic Explorer’s proprietary technology.

Read more

This technology produces PDO through the optimized fermentation of crude glycerin, a renewable feedstock..

PDO is a diol chemical building block, used in various applications including cosmetic, personal care, coatings as well as to produce polymers such as PTT (poly trimethylen terephthalate) and polyurethanes. 

Through this exclusive license, METEX will support SK Chemicals to successfully commercialize the PDO business and to benefit from expanding global demand for PDO. SK Chemicals, a leading South Korean company, has rapidly become one of the major green chemical companies through focusing on innovative chemicals and polymers and executing its vision to become a global leader for total solution provider for eco-friendly materials. SK Chemicals values METEX’s PDO technology on robustness, breadth of intellectual property and economical attractiveness.

During the last three years, METEX, a European pioneer in industrial biotechnologies, sampled several tons of PDO on the market, tested dozens of different crude glycerine grades so as to accumulate expertise and to understand better product performance and drivers in key applications.
SK Chemicals strong technology and market access in the field of chemicals and polymer business are the main reasons why METEX has finally decided to license its technology exclusively to SK Chemicals. As a consequence of this new project, METEX has terminated all other discussions with potential PDO partners as well as its negotiations aiming at resuming its industrial project in Malaysia.

This exclusive alliance based on METEX’s technology will allow SK Chemicals to invest for the commercial production of PDO. The transaction's financial terms consist of an upfront payment with subsequent milestone payments and

Limagrain inaugurated its new head office on the Biopôle Clermont-Limagne

In november 2013, the group Limagrain moved into its new head offices, a very luminous building 0f 11200 m2 organized on 3 floors, built on a plot of land of 10 ha in the northeast of the Biopole Clermont-Limagne. 

Read more

Its official inauguration took place on June 13th, 2014 in the presence of numerous personalities of the political and economic world.


The natural light is an essential element of this construction implanted in front of the volcanoes' chain, a special place was also reserved for the vegetable with in particular a 700m2 Atrium sheltering plants of the Mediterranean region.
The Group employs 1 450 people in Auvergne where it invested since 2009 about 100 M€, among which 20 M€ for the Saint-Beauzire headquarter.


For the conception, the construction and the arrangement of this site, Limagrain very mainly leaned on regional companies. It called on to the architect Denis Ameil and to the engineering consulting firm R3I.


The priority was given to the comfort of the employees, associated to the project. They are 400 today to work on the site of the Biopole Clermont-Limagne which was besides planned to receive later extensions in case of additional needs.

ANS Biotech obtains Iso 9001:2008 certification and moves to its new premises on the Biopôle Clermont-Limagne

Clermont-Ferrand, May 16th, 2014 - ANS Biotech has obtained ISO 9001:2008 certification from Intertek Certification France, validating the quality and consistency of its preclinical research services and R&D programs.

Read more

ANS Biotech is the first global CRO specialized in pain research to achieve ISO 9001:2008 certification, reaffirming the Company's strong position as an experienced preclinical research partner for customers developing new drugs in the pain field.


ANS Biotech current economic events are also marked by its recent move to new premises. The company is now domiciled on the Riom site of the Biopole Clermont-Limagne where it occupies 300 m2 and has its own space of animal housing.
These new equipments strengthen the ANS Biotech competitiveness which intends to become one of the leaders in the preclinical pain research and in molecules for antalgic applications.


Extension and development of Icare laboratories

Icare laboratories offers a panel of customized services to master the contamination, ranging from the analysis of products to the qualification of installations, including the marketing and the manufacturing of customized products. 

Read more

Created in 1995, Icare laboratories built in 2002 their premises on the Biopole Clermont-Limagne, Saint-Beauzire: 2000 m2 which the company intends to carry in 6000 m2 within the next 10 years, through an ambitious development plan which aims at tripling the capacity of the company. 


To industrialize its activity of production (cultural media, thinners and reagents), the company finishes the construction of new 1000 m2 dedicated to sterility tests, to the manufacture of culture media, the laundry and the decontamination of waste. Its extension will also allow the company to have a class A in B zone for the execution of sterility tests for pharmaceutical products and medical devices, as well as a P3 laboratory and a “souchothèque”. 


The development strategy of Icare involves important investments in equipment and the construction of new laboratories. It also includes an active approach for an international growth. The company has also acquired in 2012 the company QUALISTE, based itself in Montpellier. This service company which employs 8 people, experts, consultants, engineers and technicians then came to complete the skills of Icare in term of validation and qualification of processes. 


E-Phys, a new actor in the field of pain

E-Phys is a young innovative company serving academic and industrial research teams working on the development of pain drugs. 

Read more

E-Phys realizes preclinical tests based on in vivo electrophysiology techniques in anaesthetised rodents. These tests, in conjunction with others techniques, improve the prediction of therapeutic effectiveness of drug candidates before clinical trials. 


E-Phys settled its own in vivo electrophysiology platform within the Faculty of Medicine and Pharmacy (University of Auvergne) and established its head office in the Biopole Clermont-Limagne, in Saint-Beauzire. 


E-Phys intends to become within 3 years a renowned and unavoidable actor of the R&D in algology. 



Hybrigenics launches Helixio, its new branch dedicated to genomic services

Hybrigenics, a bio-pharmaceutical group with a focus on research and development of new treatments against proliferative diseases and specialized in protein interaction, launches Helixio, its new branch dedicated to genomic services. 

Read more

With the acquisition of the genomic division of Imaxio in 2013, Hybrigenics has gained access to the latest state-of-art technologies based on DNA or RNA microarrays (“chips”) and on next generation sequencing. Hybrigenics wants to expand this activity by marketing it under the new name of Helixio® to the existing 1,500+ strong academic and industrial client base of Hybrigenics Services, its proteomic branch, and to the widest and most diversified life science communities. 


Helixio is targeting the booming market of genomic services, allowong the customers to swiftly switch from gene to protein or from protein to gene as the center piece of their research interest, within the same Hybrigenics group. This one-stop shop offer of both genomic and proteomic services will represent a distinctive advantage in terms of project followup and extended client satisfaction. 

Saint-Beauzire : inauguration on the Biopôle Clermont-Limagne of the inter-company-restaurant

At the end of 2013, the site of Saint-Beauzire welcomed 1300 employees notably thanks to the setting-up on the park of the Limagrain group headquarter. This new size allows today the zone to benefit from service facilities for its users: public transportation with the passage of a bus line, an inter-company day-nursery and an inter-company restaurant. 

Read more

To inaugurate this restaurant, that February 17th, company directors, elected representatives and designers of the project met, the opportunity for all these actors to review the first months of functioning of the restaurant and to congratulate themselves on its success. 


The restaurant is administered by Biopole Restauration, an association grouping user companies. It has delegated to the Puy-de-Dôme Chamber of Commerce the current management of the restaurant while Elior is the company in charge of the catering. 



390 meals served per day 


At the end of February, 390 meals were served each day including 210 Meals on Wheels, an attendance which illustrates the satisfaction of users. 
A particular attention is paid to the quality of meals, manufactured in situ with a maximum of products coming from local producers. So, with the arrival of sunny days, the restaurant will propose a fast catering service for the best possible satisfaction of user requirements. 


Peace and light: architecture focused on comfort of users 


The restaurant is implanted in the continuation of the main path of the Biopole, at the heart of the zone, on a location dedicated to service facilities (by its side, the day-nursery is also opened since the autumn). 

The architects paid close attention to the well-being of the users. 

The dining room is designed in a spacious half circle illuminated by a wide plate glass window opened on the peaceful landscape of “chaîne des puys”. The users also appreciate the remarkable acoustic qualities of this room, a criterion of essential comfort for the quality of moments meal. 


Finally, another quality was given from its conception to the building: the modularity. And considering the evolution of its attendance, all the actors of the inter-company restaurant already agree to envisage the next enlargement of the dining room. 





RIE : who does What ?
Real estate investor: SR developer
Architect: Ameil Architecte
Cateting : Elior
Administrator: Biopôle Restauration
Delegated to the management: CCI of Puy-de-Dôme 

Intercompanies day-nursery, company restaurant, public transport: employee services are being put in place in the Saint-Beauzire site

The employees of the Biopole are offered of new services on the Saint-Beauzire site : childcare facilities for children under the age of 4 years, an intercompany restaurant and a bus line connecting the site with the Clermont area.

Read more

A day-nursery on the Biopôle Clermont-Limagne…

Among its users, the Biopole Clermont-Limagne counts from now on about twenty old toddlers from a few months to 4 years of age.
Since the fall of 2013, the Saint-Beauzire site has an inter-entreprise crèche, inaugurated on december 10. Located in the heart of the new service area, the company day-nurseries Tipipôle offers real advantages to working parents: financial participation of their company, proximity and reduction in transport time, working time adapted to the reality of companies.
Tipipôle is the 3rd intercompanies day-nursery created on the clermont urban area by " Jour de crèche”, a company specialized in the creation of day care facilities for small children.
Of a surface about 300 m2, the establishment is also opened on the outside with 250 m2 of yard, playground and garden.
The children are welcomed by a team of seven professionals there, from Monday to Friday, from 8:00 am till 7:00 pm.


…an intercompany restaurant

Beside the day-nursery, the new intercompany restaurant welcomes the employees each noon hour since November.
The user companies grouped together in association to allow their employees to reach this restaurant endowed with a room of 400 m2 widely glazed and with a current capacity of 450 meals a day.
In the beautiful days, the users can also take a snatch outside on a terrace planned for that purpose.


and public transport

The increasing needs in transport, expressed both by the users of the Biopole Clermont-Limagne and by the inhabitants of Saint-Beauzire led the municipality to subscribe to the SMTC, allowing to enter in the urban transport zone.
From January 2nd, 2014, the bus line number 33 will daily connect Clermont-Ferrand with Saint-Beauzire (three stops in Saint-Beauzire of which one on the Biopole Clermont-Limagne).
9 round trips a day are planned from Monday to Friday, 4 every Saturday.

Carbios launches its initial public offering on alternext Paris

The green chemistry company Carbios, announced on November 29th its initial public offering on Alternext Paris.

Read more

Specialized in the development of high technologies for recovery of plastics waste and production of bio-polymers, Carbios has three axes of development : the creation of a new generation of plastics which can auto-degrade at the end of life, the biological recycling of plastic waste, and the production of biopolymers (production of oil-free plastics). 

Carbios developed a platform of bioprocesses and industrial solutions named Thanaplast ™.  Programmed over 5 years, this project weighs 22 million euros among which 15 millions are solely worn by Carbios.  It gathers 60 researchers, renowned partners (Limagrain, Barber, Deinove, INRA, CNRS -NATIONAL CENTER FOR SCIENTIFIC RESEARCH- , University of Poitiers) and benefits from the support of Bpi France (9,6 millions among which 6,8 millions for Carbios).

The issue of new shares and the admission for trading of the shares of the Company on the Alternext market of Euronext Paris are intended to provide for the company additional means to secure and accelerate its development and pass in the pre-industrial phase.

Through this operation, the company will proceed to a capital increase about 10 ME. The investment is opened until December 12th, 2013. 

Neuronax : NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries

Neuronax announced that the European Commission has granted the Orphan Drug Designation to its lead compound, NX210, for the treatment of Spinal Cord Injuries. 

Read more

Neuronax is currently preparing the entry in clinical trial of the NX210, a peptide which presents a multifunctional activity: it has capacities to counteract the death of the nervous cells and to stimulate their regeneration. While acting directly on the survival and the plasticity of the neural cells, this molecule was able to promote the growth of nervous fibers and the establishment of connections supporting a significant functional recovery in preclinical studies.
“The Orphan Drug Designation is an important step in the development of NX210. It encourages us to go further and to evaluate the potential of thiss candidate-drug in the treatment of spinal cord injury, a disorder for which there no fully satisfactory therapeutic option exists at the present time" indicates Stéphane Gobron, CEO&CSO of Neuronax.

About European Orphan Drug Designation
European Orphan Drug Designation is granted by the European Commission following the positive recommendation of the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) for a medicine which has the potential for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions that affect fewer than 5 in 10 000 people in the European. This status gives certain incentives during the development phase including protocol assistance in optimizing the clinical development and a market exclusivity in the disease concerned for a period of up to 10 years in the European Union.

About Neuronax
Neuronax is a biotechnological company focused on the development of candidate-drugs supporting neural repair in order to treat traumatic or severe degenerative disorders of the central nervous system (CNS). Set up in 2003, the company is based on research programs allowing the discovery and characterization of new innovative first-in class molecules, including NX210, able to support survival and plasticity of neural cells. Firstly focused on spinal cord injury, the neuroregenerative properties of these compounds can be considered to address various other unmet medical needs in the CNS area.

Alzheimer: Cyclopharma partner of Eli Lilly for the manufacturing of Amyvid

Laboratoires Cyclopharma, a specialized radiopharmacy company, signed a cooperation agreement with Eli Lilly for the manufacturing of Amyvid.

Read more

This product injected into the patients before a PET imaging session (position emission tomography) highlights amyloid plaques present in the Alzheimer's disease and in other cognitive impairment pathologies. 

Amyvid is the first one and the only radiopharmaceutical product to receive the marketing authorization in Europe and in the USA for this pathology. 

The use of the PET comes as a supplement to the other valuation methods for Alzheimer's disease and will allow an early diagnosis. Alzheimer's disease affects in France more than 800 000 patients. In the world, a new case is diagnosed every 7 seconds. 

Hybrigenics acquires the genomic activities of Imaxio - Pradeyrol Développement invests 1,3 million euros in Hybrigenics

The bio-pharmaceutical company Hybrigenics announced the acquisition of the genomic activities of Imaxio and a EUR 1.3 million fund raising through a private placement reserved to Pradeyrol Development. 

Read more

Based in the Clermont-Limagne Biopole (Saint-Beauzire site) the genomics unit of Imaxio performs fee-for-service studies specialized in extracting and sequencing DNA or RNA to get information on the genome and gene expression from any living organism, in normal or pathological conditions. 

This information is crucial in many applications such as the diagnosis of genetic disease, the profiling of cancers to choose the right treatment (the so-called "personalized medicine"), the direct identification of bacterial or viral strains, or the characterization of improved plant cultivars. 

More specifically, the genomics division of Imaxio is one of the few European service providers certified by Agilent to perform its SureSelect® target enrichment, comparative genomic hybridization (CGH) and microRNA microarrays technologies. It also operates an Illumina® next generation sequencing and genotyping platform. 

GREENTECH : a new parnership in Madagascar

After the Peru and the Burkina Faso, GREENTECH begins a new convention with Madagascar. 

Read more

GREENTECH is closely working with the University of Antsiranana. For this purpose, the university provided available space. GREENTECH has equipped in research laboratory, specifically for the development of new cosmetic active compounds. GREENTECH has supplied all necessary equipment for plant extraction and analytical control of these cosmetic ingredients.
A new common structure GREENMadag has been especially created for the development of new actives from local flora rich in medicinal applications. As well, an educational program for the formation of competent technicians is in progress.
First steps of development of cosmetic ingredients and extractions assays will be realised in this GREENMadag laboratory and then scale-up phases will be perform in GREENTECH laboratory.

In this way, this will be locally new add-valued market for producers of raw materials, new employment for engineers and technicians in Madagascar and thus new income for local communities. 

Carbios signs a €7 million strategic collaboration with INRA at the Toulouse White Biotechnology

Carbios, a green chemistry company that specializes in innovative biological and industrial processes for recovering plastic waste and is developing competitive production processes for biosourced plastics and biopolymers, today announced the signature of a pivotal €7-million collaboration with the French National Institute for Agricultural Research (INRA) at the Toulouse White Biotechnology (TWB) research center.

Read more

The project is part of the THANAPLAST™ private-public consortium on plastics lead by Carbios  and that brings together CARBIOS’ different corporate and academic partners (The CNRS, the INRA, the Université de Poitiers, Deinove, the Barbier Group, and the Limagrain Group). 


The Carbios-INRA project will focus on the development 
 of innovative bioprocesses for recovering plastic waste and producing biopolymers. 

Carbios and INRA are both members of the TWB research center  and will share know-how, expertise and human & technical resources over a five-year period. The goal is to develop effective biobased industrial processes that (as an alternative to conventional chemistry) add value to plastic waste and enable the production of economically competitive biosourced polymers.
The multidisciplinary collaboration will include R&D staff from TWB, the 3BCar Carnot Institute and two INRA groups (from the MICALIS laboratory in Paris and the Biological Systems and Processes Engineering Laboratory from INSA Toulouse, both of which are led by Alain Marty, Emeritus Professor of Enzymology). The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.
This project will enable Carbios to better address environmental, societal and economic issues concerning the recovery of plastic waste. Intensive exploitation of plastics means that over 100 million tons of plastic waste is generated worldwide every year. This alarming environmental issue has prompted a collective awareness of the need to find alternative production and consumption paradigms for a sustainable, environmentally responsible future. Carbios is developing innovative industrial solutions for transforming plastic waste into a novel, high-quality, renewable raw material for the plastics industry. The company offers a viable economic alternative to the depletion of agricultural resources (which might better be used to feed people) and the rarefaction of fossil fuels.


The €7 million collaboration will be included in the THANAPLASTTM consortium's overall budget of €22 million over five years. This consortium will bring together 60 researchers and will also receive €9.6 million in financial support from the French state innovation agency OSEO as part of the latter’s Strategic Industrial Innovation program. CARBIOS (as the project’s initiator and leader) will contribute most of the budget (€15 million) and will receive €6.8 million of the €9.6 million provided by OSEO.
THANAPLAST™ is seeking to create industrial value from plastics that have come to the end of their useful lives. The consortium will leverage biological catalysts with exceptional properties (e.g. resistance to heat, extreme pH and specific chemical reactions) and will develop and patent innovative technologies for producing, transforming and recycling a broad range of plastic materials. 

LEXVA Analytique laboratory joins the Biopôle Clermont-Limagne

LEXVA Analytique is a physico-chemical analyses laboratory which addresses all the industries in general and the cosmetic, perfume, food-processing industries and parapharmaceuticals in particular.

Read more


Created in 2007, the laboratory benefits from 30 years experience in the methods of analysis and research on essential oils, previously developed within the laboratory of Essential Oils managed by Dr Jean-Claude CHALCHAT at the Blaise Pascal University (Clermont-Ferrand). As such, LEXVA Analytique possesses a reference bank of chromatograms on more than 400 essential oils.
The laboratory, thanks to its diverse equipments, proposes to its customers analyses upon request, from the screening for a compound to quantification.

Within the framework of its development, the LEXVA Analytique laboratory chose the site of Saint-Beauzire to construct its own building. The company will join the Biopole Clermont-Limagne in September, 2013, in premises with close to 250 square meters of floor space. 


Opening up NEURONAX’s capital, start-up specialized in neurorepair

Alzheimer and Parkinson diseases, multiple sclerosis or traumas (brain and spinal cord injury, strokes …): it is estimated that in France about one in ten people is impacted with disease affecting the central nervous system. Neuronax is a biotech start-up specialized in the development of therapeutic molecules applied to neurological disorders. 

Read more

Created in 2003, it has developed NX210, a drug candidate dedicated to the treatment of spinal cord injury. 

This class of molecule presents a multi-functional activity: it has capacities to reduce the death of nerve cells while stimulating their regeneration. The encouraging results obtained to the animal allow from now on Neuronax to approach the phase I/IIa clinical trial. 


The objective of Neuronax today: obtain the proof of clinical concept of the NX210 in humans 

In France, approximately 1200 persons are victims every year of spinal cord injury and we consider at 1,3 millions in the world, the number of persons affected by a cord injury. 

Whereas no treatment is at present available for these affections, the neurorepair activities of NX210 suggest an important potential by acting directly on the survival and the plasticity of nerve cells. The molecule is indeed able to promote the regrowth of nerve fibbers and the establishment of connections so favouring a significant functional covering to the hurt animal. These results must be validated from now in humans. It is exactly to finance this phase that NEURONAX launches a 900 000-euro fund raising. This sum will also allow to undertake preclinical researches on a second generation of molecule (NS640). 


Various partners are already associated to this operation of which in particular Sofimac Partners and Oséo. With WiSEED (, platform of crowd-funding dedicated to the innovation, the opportunity is offered to the private individuals to participate to the capital round in placing subscription orders*. It is so possible to invest on-line, from 100 euros and to become a Neuronax shareholder. 


*Execution of the orders of subscription is assured by the execution of orders department dispensed by AM France SAS, Investment services provider approved by the Authority of Prudential control ( ACP) under the n°CIB 181 73D, and the program of activity of which was approved by the Authority of Financial markets ( AMF). 

Biofilm Control : the Biofilm project selected in the 15th call for proposals of the Poles of Excellence

The BIOFILM project was deposited by Biofilm Control in partnership with BioMérieux, and with 5 University Hospital Centres (Clermont-Fd, Lyon, Grenoble, Nîmes and Strasbourg). It aims at developing a new theranostic tool for the prescription of antibiotics called Antibiofilmogramme®. 

Read more

Antibiofilmogramme® has for peculiarity to estimate the efficiency of antibiotics by taking into account the “biofilm” behaviour of bacteria, what will lead to reduce treatment failures and the appearance of resistance to antibiotics. It brings a double competitive advantage: fast results (between 2 and 6 hours) and new clinically relevant information (biofilm behaviour). 

This project is a part of 72 new projects of collaborative R&D supported by the Interministerial Unique Fund within the framework of the 15th call for proposals of the Poles of Excellence*. 

On a world market of antibiotic susceptibility testing of the order of 1 billion euros, Biofilm Control has for objective to launch on the market its new generation of theranostic tools, Antibiofilmogramme®. 
The double competitive advantage (speed and new information of clinical interest) will allow market share gains and will generate royalties of the order of several tens of millions of euros. 

In parallel, the company plans to pursue the developments of new generations of diagnosic tests in Microbiology, but also in Immunohematology. The Biomfilm project should also entail the creation of about fifteen jobs distributed at seven partners. 


 *72 selected projects will receive a help of the 63,5 million euro from state and will also benefit from the assistance of local authorities and community funds (ERDF) at the level of 43,9 million euros.